    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                               	     <!DOCTYPE html><html><head><script id="f5_cspm">(function(){var f5_cspm={f5_p:'NNPPBPMEMFDCOPBCFFDLBOJCKDIPGGMDFBCFNIPOIFIBHFDGMJEOLEMFBJJADIGNEPFDBFDPPDGKMMCCBLOJIFNAPNPEJGLAJCOGCIADHDKDMJOMCCNKIMDLBHEIIOLH',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}return;}}catch(err){return;}setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}f5_cspm.go();}());</script>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - PRADAXA- dabigatran etexilate mesylate capsule  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "PRADAXA- dabigatran etexilate mesylate capsule <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">PRADAXA- dabigatran etexilate mesylate capsule <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APRADAXA%2D%20Dabigatran%20Etexilate%20Mesylate%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dba74e3cd%2Db06f%2D4145%2Db284%2D5fd6b84ff3c9%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=carton014954.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=carton014954.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" src="image.cfm?type=img&name=carton014954.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=carton014960.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=carton014960.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" src="image.cfm?type=img&name=carton014960.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                    <h4 class="more closed">VIEW MORE</h4>                                        <div class="show-more">                                            <ul>                                                                                                                        <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=label014954.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="2">                                                <img id="zoom_3" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=label014954.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" src="image.cfm?type=img&name=label014954.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=carton013554.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="3">                                                <img id="zoom_4" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=carton013554.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" src="image.cfm?type=img&name=carton013554.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                                                                           <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=carton013560.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="4">                                                <img id="zoom_5" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=carton013560.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" src="image.cfm?type=img&name=carton013560.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=carton013512.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="5">                                                <img id="zoom_6" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=carton013512.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" src="image.cfm?type=img&name=carton013512.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                                                                           <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=label013554.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="6">                                                <img id="zoom_7" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=label013554.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" src="image.cfm?type=img&name=label013554.jpg&setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                            </ul>                                     </div>                                                                 </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22DABIGATRAN%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=DABIGATRAN" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=DABIGATRAN" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DABIGATRAN[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DABIGATRAN/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DABIGATRAN/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DABIGATRAN/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DABIGATRAN[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=DABIGATRAN+ETEXILATE+MESYLATE&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    0597-0135-12,                                                                                                                                        	                                    0597-0135-54,                                                                                                                                        	                                    0597-0135-60,                                                                                                                                        	                                    0597-0149-12,                                                                        	<a class="view-more show-js" href="#">view more</a><div class="more-codes"><span>                                                                                                                                        	                                    0597-0149-54,                                                                                                                                        	                                    0597-0149-60                                                                                                                                                                        	</span>                                    </div>                                                                								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Boehringer Ingelheim Pharmaceuticals Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	01/15                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&amp;type=pdf&amp;name=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&amp;type=zip&amp;name=PRADAXA">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="Section_00"></a>  <a name="section-1"></a>   <p></p>   <h1>WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA</h1>   <p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <a name="p258926221358778759"></a><span class="XmChange"><span class="Bold">(A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS<br />Premature discontinuation of any oral anticoagulant, including PRADAXA, increases the risk of thrombotic events. If anticoagulation with PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see Dosage and Administration <a href="#Section_2.4">(2.4</a>, <a href="#Section_2.5">2.5</a>, <a href="#Section_2.6">2.6)</a> and Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span>.</span> <br /> <br /> <span class="Bold">(B) SPINAL/EPIDURAL HEMATOMA<br />Epidural or spinal hematomas may occur in patients treated with PRADAXA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:</span></span> </p>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <a name="p379042281397499567"></a><span class="XmChange"><span class="Bold"> • use of indwelling epidural catheters<br /> • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants<br /> • a history of traumatic or repeated epidural or spinal punctures<br /> • a history of spinal deformity or spinal surgery<br /> • optimal timing between the administration of PRADAXA and neuraxial procedures is not known <span class="Italics">[see Warnings and Precautions <a href="#Section_5.3">(5.3)</a>]</span>.</span></span> </p>   <p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <a name="p271691281396882045"></a><span class="XmChange"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary <span class="Italics">[see Warnings and Precautions <a href="#Section_5.3">(5.3)</a>]</span>.<br /> <br />Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated <span class="Italics">[see Warnings and Precautions <a href="#Section_5.3">(5.3)</a>]</span>.</span></span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA.    <br />    <br />PRADAXA&reg; (dabigatran etexilate mesylate) capsules for oral use   <br />Initial U.S. Approval: 2010  </div>   <div class="Warning">    <div>     <h1 class="Warning"> <span class="Bold">WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA</span> <br /> <span class="Italics">See full prescribing information for complete boxed warning</span> <br /> <br /> <span class="Bold">(A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including PRADAXA, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy (<a href="#Section_2.4">2.4</a>, <a href="#Section_2.5">2.5</a>, <a href="#Section_2.6">2.6</a>, <a href="#Section_5.1">5.1</a>).</span> <br /> <br /> <span class="Bold">(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with PRADAXA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis (<a href="#Section_5.3">5.3</a>). Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated (<a href="#Section_5.3">5.3</a>).</span> </h1>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <a name="t23087622"></a>     <table border="0" width="85%">      <colgroup>       <col />       <col align="right" />      </colgroup>      <tbody class="Headless">       <tr>        <td><a href="#Section_00">Boxed Warning</a></td>       <td align="right">4/2014</td>       </tr>       <tr>        <td>Indications and Usage <a href="#Section_1.1">(1.1</a>, <a href="#Section_1.2">1.2</a>, <a href="#Section_1.3">1.3)</a></td>       <td align="right">4/2014</td>       </tr>       <tr>        <td>Dosage and Administration <a href="#Section_2.1">(2.1</a>, <a href="#Section_2.3">2.2)</a></td>       <td align="right">1/2015</td>       </tr>       <tr>        <td>Warnings and Precautions <a href="#Section_5.1">(5.1</a>, <a href="#Section_5.3">5.3</a>, <a href="#Section_5.5">5.5)</a></td>       <td align="right">4/2014</td>       </tr>      </tbody>     </table>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">PRADAXA is a direct thrombin inhibitor indicated: </p>     <ul class="Disc">      <li>To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation <a href="#Section_1.1">(1.1)</a> </li>      <li>For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days <a href="#Section_1.2">(1.2)</a> </li>      <li>To reduce the risk of recurrence of DVT and PE in patients who have been previously treated <a href="#Section_1.3">(1.3)</a> </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Underline">Non-valvular Atrial Fibrillation:</span>       <ul class="Circle">        <li>For patients with CrCl &gt;30 mL/min: 150 mg orally, twice daily <a href="#Section_2.1">(2.1)</a> </li>        <li>For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily <a href="#Section_2.1">(2.1)</a> </li>       </ul> </li>      <li> <span class="Underline">Treatment of DVT and PE:</span>       <ul class="Circle">        <li>For patients with CrCl &gt;30 mL/min: 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation <a href="#Section_2.1">(2.1)</a> </li>       </ul> </li>      <li> <span class="Underline">Reduction in the Risk of Recurrence of DVT and PE:</span>       <ul class="Circle">        <li>For patients with CrCl &gt;30 mL/min: 150 mg orally, twice daily after previous treatment <a href="#Section_2.1">(2.1)</a> </li>       </ul> </li>      <li>Instruct patients not to chew, break, or open capsules <a href="#Section_2.3">(2.3)</a> </li>      <li>Review recommendations for converting to or from other oral or parenteral anticoagulants <a href="#Section_2.4">(2.4</a>, <a href="#Section_2.5">2.5)</a> </li>      <li>Temporarily discontinue PRADAXA before invasive or surgical procedures when possible, then restart promptly <a href="#Section_2.6">(2.6)</a> </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <p class="Highlighta">Capsules: 75 mg and 150 mg <a href="#Section_3">(3)</a> </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <ul class="Disc">      <li>Active pathological bleeding <a href="#Section_4">(4)</a> </li>      <li>History of serious hypersensitivity reaction to PRADAXA <a href="#Section_4">(4)</a> </li>      <li>Mechanical prosthetic heart valve <a href="#Section_4">(4)</a> </li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul class="Disc">      <li>Bleeding: PRADAXA can cause serious and fatal bleeding <a href="#Section_5.2">(5.2)</a> </li>      <li>Bioprosthetic heart valves: PRADAXA use not recommended <a href="#Section_5.4">(5.4)</a> </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Most common adverse reactions (&gt;15%) are gastritis-like symptoms and bleeding <a href="#Section_6.1">(6.1)</a> </p>     <br />     <p class="Highlighta"> <span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or </span></span><span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span>. </p>     <br />    </div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul class="Disc">      <li>P-gp inducers rifampin: Avoid coadministration with PRADAXA <a href="#Section_5.5">(5.5)</a> </li>      <li>P-gp inhibitors in patients with CrCl 30-50 mL/min: Consider reducing dose or avoid <a href="#Section_7">(7)</a> </li>      <li>P-gp inhibitors in patients with CrCl &lt;30 mL/min: Not recommended <a href="#Section_7">(7)</a> </li>     </ul>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <p class="Highlighta">Geriatric use: Risk of bleeding increases with age <a href="#Section_8.5">(8.5)</a> </p>     <br />    </div>    <div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>    </div>   </div>   <div></div>   <div></div>   <div>    <div></div>    <div>     <div></div>    </div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>   </div>   <div></div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 1/2015</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc">WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA</a> </h1>   <h1> <a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a> </h1>   <h2> <a href="#section-1.1" class="toc">1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-1.2" class="toc">1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism</a> </h2>   <h2> <a href="#section-1.3" class="toc">1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</a> </h2>   <h1> <a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION </a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 Recommended Dose</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Dosing Adjustments</a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Instructions to Patients</a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Converting from or to Warfarin</a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Converting from or to Parenteral Anticoagulants</a> </h2>   <h2> <a href="#section-2.6" class="toc">2.6 Discontinuation for Surgery and Other Interventions</a> </h2>   <h1> <a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4  CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Increased Risk of Thrombotic Events after Premature Discontinuation</a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Risk of Bleeding</a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Spinal/Epidural Anesthesia or Puncture</a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves</a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure</a> </h2>   <h1> <a href="#section-6" class="toc">6  ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a> </h2>   <h1> <a href="#section-7" class="toc">7  DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</a> </h2>   <h1> <a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.2 Labor and Delivery</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.6" class="toc">8.6 Renal Impairment</a> </h2>   <h1> <a href="#section-9" class="toc">10  OVERDOSAGE</a> </h1>   <h1> <a href="#section-10" class="toc">11  DESCRIPTION</a> </h1>   <h1> <a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-11.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h1> <a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-13" class="toc">14  CLINICAL STUDIES</a> </h1>   <h2> <a href="#section-13.1" class="toc">14.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-13.2" class="toc">14.2 Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</a> </h2>   <h1> <a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a> </h1>   <h2> <a href="#section-15.1" class="toc">17.1 Instructions for Patients</a> </h2>   <h2> <a href="#section-15.2" class="toc">17.2 Bleeding</a> </h2>   <h2> <a href="#section-15.3" class="toc">17.3 Gastrointestinal Adverse Reactions</a> </h2>   <h2> <a href="#section-15.4" class="toc">17.4 Invasive or Surgical Procedures</a> </h2>   <h2> <a href="#section-15.5" class="toc">17.5 Concomitant Medications</a> </h2>   <h2> <a href="#section-15.6" class="toc">17.6 Prosthetic Heart Valves</a> </h2>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1  INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="Section_1"></a>  <a name="section-1"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_1.1"></a>   <a name="section-1.1"></a>    <p></p>    <h2>1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</h2>    <p class="First" style="border-left:1px solid;"> <a name="p2740112281396882255"></a><span class="XmChange">PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_1.2"></a>   <a name="section-1.2"></a>    <p></p>    <h2>1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism</h2>    <p class="First" style="border-left:1px solid;"> <a name="p276558281396882263"></a><span class="XmChange">PRADAXA is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_1.3"></a>   <a name="section-1.3"></a>    <p></p>    <h2>1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</h2>    <p class="First" style="border-left:1px solid;"> <a name="p276625281396882271"></a><span class="XmChange">PRADAXA is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated.</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2  DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="Section_2"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.1"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 Recommended Dose</h2>    <a name="t23336428"></a>    <div class="scrollingtable">    <table border="1" frame="box" rules="none" width="75%">      <colgroup>       <col />       <col />      </colgroup>      <thead>       <tr class="First Last">        <th class="Botrule Lrule Rrule Toprule" align="center"><span class="XmChange">Indication</span></th>       <th class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="XmChange">Dosage</span></th>       </tr>      </thead>      <tbody>       <tr class="First" valign="top">        <td class="Botrule Lrule Rrule Toprule" rowspan="5"><span class="XmChange"><span class="Bold">Reduction in Risk of Stroke and Systemic Embolism in Non-valvular AF</span></span></td>       <td><span class="XmChange">CrCl &gt;30 mL/min: </span> <br /> <br /> </td>       <td class="Rrule Toprule"><span class="XmChange">150 mg twice daily</span> <br /> <br /> </td>       </tr>       <tr valign="top">        <td><span class="XmChange">CrCl 15 to 30 mL/min:</span> <br /> <br /> </td>       <td class="Rrule"><span class="XmChange">75 mg twice daily </span> <br /> <br /> </td>       </tr>       <tr valign="top">        <td class="Botrule"><span class="XmChange">CrCl &lt;15 mL/min or on dialysis:</span> <br /> </td>       <td class="Botrule Rrule"><span class="XmChange">Dosing recommendations cannot be provided</span> <br /> </td>       </tr>       <tr valign="top">        <td class="Toprule"><span class="XmChange">CrCl 30 to 50 mL/min with concomitant use of P-gp inhibitors:</span> <br /> <br /> </td>       <td class="Rrule Toprule"><span class="XmChange">Consider reducing dose to 75 mg twice daily if given with P-gp inhibitors dronedarone or ketoconazole. Dose adjustment is not necessary when co-administered with other P-gp inhibitors</span> <br /> <br /> </td>       </tr>       <tr valign="top">        <td class="Botrule"><span class="XmChange">CrCl &lt;30 mL/min with concomitant use of P-gp inhibitors:</span> <br /> </td>       <td class="Botrule Rrule"><span class="XmChange">Avoid co-administration</span> <br /> </td>       </tr>       <tr valign="top">        <td class="Botrule Lrule Rrule Toprule" colspan="1" rowspan="3"><span class="XmChange"><span class="Bold">Treatment of DVT and PE<br /> <br />Reduction in the Risk of Recurrence of DVT and PE</span></span></td>       <td class="Toprule"><span class="XmChange">CrCl &gt;30 mL/min:</span> <br /> <br /> </td>       <td class="Rrule Toprule"><span class="XmChange">150 mg twice daily</span> <br /> <br /> </td>       </tr>       <tr valign="top">        <td class="Botrule"><span class="XmChange">CrCl ≤30 mL/min or on dialysis:</span> <br /> </td>       <td class="Botrule Rrule"><span class="XmChange">Dosing recommendations cannot be provided</span> <br /> </td>       </tr>       <tr class="Last" valign="top">        <td class="Botrule Toprule"><span class="XmChange">CrCl &lt;50 mL/min with concomitant use of P-gp inhibitors: </span> <br /> </td>       <td class="Botrule Rrule Toprule"><span class="XmChange">Avoid co-administration</span> <br /> </td>       </tr>      </tbody>     </table>   </div>    <p class="First" style="border-left:1px solid;"> <a name="p284211281396886021"></a><span class="XmChange"><span class="Italics"><span class="Underline">Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</span></span></span> </p>    <p> <a name="p549122"></a>For patients with creatinine clearance (CrCl) &gt;30 mL/min, the recommended dose of PRADAXA is 150 mg taken orally, twice daily. For patients with severe renal impairment (CrCl 15-30 mL/min), the recommended dose of PRADAXA is 75 mg twice daily <span class="Italics">[see Use in Specific Populations <a href="#Section_8.6">(8.6)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>].</span> Dosing recommendations for patients with a CrCl &lt;15 mL/min or on dialysis cannot be provided.</p>    <p style="border-left:1px solid;"> <a name="p7993281396886120"></a><span class="XmChange"><span class="Italics"><span class="Underline">Treatment of Deep Venous Thrombosis and Pulmonary Embolism</span></span></span> </p>    <p style="border-left:1px solid;"> <a name="p284353281396886133"></a><span class="XmChange">For patients with CrCl &gt;30 mL/min, the recommended dose of PRADAXA is 150 mg taken orally, twice daily, after 5-10 days of parenteral anticoagulation. Dosing recommendations for patients with a CrCl ≤30 mL/min or on dialysis cannot be provided <span class="Italics">[see Use in Specific Populations <a href="#Section_8.6">(8.6)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>].</span></span> </p>    <p style="border-left:1px solid;"> <a name="p378892281421946169"></a><span class="XmChange"><span class="Italics"><span class="Underline">Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</span></span></span> </p>    <p style="border-left:1px solid;"> <a name="p310217281421942293"></a><span class="XmChange">For patients with CrCl &gt;30 mL/min, the recommended dose of PRADAXA is 150 mg taken orally, twice daily after previous treatment. Dosing recommendations for patients with a CrCl ≤30 mL/min or on dialysis cannot be provided <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>) and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span></span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Dosing Adjustments</h2>    <p class="First"> <a name="p777122"></a>Assess renal function prior to initiation of treatment with PRADAXA. Periodically assess renal function as clinically indicated (i.e., more frequently in clinical situations that may be associated with a decline in renal function) and adjust therapy accordingly. Discontinue PRADAXA in patients who develop acute renal failure while on PRADAXA and consider alternative anticoagulant therapy.</p>    <p> <a name="p782122"></a>Generally, the extent of anticoagulation does not need to be assessed. When necessary, use aPTT or ECT, and not INR, to assess for anticoagulant activity in patients on PRADAXA <span class="Italics">[see Warnings and Precautions <a href="#Section_5.2">(5.2)</a> and Clinical Pharmacology <a href="#Section_12.2">(12.2)</a>]</span>.</p>    <p style="border-left:1px solid;"> <a name="p801122"></a><span class="XmChange"><span class="Italics"><span class="Underline">Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</span></span></span> </p>    <p> <a name="p10533281396886379"></a>In patients with moderate renal impairment (CrCl 30-50 mL/min), concomitant use of the P-gp inhibitor dronedarone or systemic ketoconazole can be expected to produce dabigatran exposure similar to that observed in severe renal impairment. Consider reducing the dose of PRADAXA to 75 mg twice daily<span class="Italics"> [see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>, Drug Interactions <a href="#Section_7.1">(7.1)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>.</p>    <p style="border-left:1px solid;"> <a name="p284563281396886433"></a><span class="XmChange"><span class="Italics"><span class="Underline">Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</span></span></span> </p>    <p style="border-left:1px solid;"> <a name="p284583281396886437"></a><span class="XmChange">Dosing recommendations for patients with CrCl ≤30 mL/min cannot be provided. Avoid use of concomitant P-gp inhibitors in patients with CrCl &lt;50 mL/min <span class="Italics">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>, Drug Interactions <a href="#Section_7.2">(7.2)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.3"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Instructions to Patients</h2>    <p class="First"> <a name="p1031122"></a>Instruct patients to swallow the capsules whole. PRADAXA should be taken with a full glass of water. Breaking, chewing, or emptying the contents of the capsule can result in increased exposure <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>    <p> <a name="p1044122"></a>If a dose of PRADAXA is not taken at the scheduled time, the dose should be taken as soon as possible on the same day; the missed dose should be skipped if it cannot be taken at least 6 hours before the next scheduled dose. The dose of PRADAXA should not be doubled to make up for a missed dose.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.4"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Converting from or to Warfarin</h2>    <p class="First"> <a name="p1052122"></a>When converting patients from warfarin therapy to PRADAXA, discontinue warfarin and start PRADAXA when the INR is below 2.0.</p>    <p> <a name="p1055122"></a>When converting from PRADAXA to warfarin, adjust the starting time of warfarin based on creatinine clearance as follows:</p>    <ul class="Disc">     <li>For CrCl ≥50 mL/min, start warfarin 3 days before discontinuing PRADAXA.</li>     <li>For CrCl 30-50 mL/min, start warfarin 2 days before discontinuing PRADAXA.</li>     <li>For CrCl 15-30 mL/min, start warfarin 1 day before discontinuing PRADAXA.</li>     <li>For CrCl &lt;15 mL/min, no recommendations can be made.</li>    </ul>    <p> <a name="p1072122"></a>Because PRADAXA can increase INR, the INR will better reflect warfarin’s effect only after PRADAXA has been stopped for at least 2 days <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.2">(12.2)</a>]</span></span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.5"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Converting from or to Parenteral Anticoagulants</h2>    <p class="First"> <a name="p1298122"></a>For patients currently receiving a parenteral anticoagulant, start PRADAXA 0 to 2 hours before the time that the next dose of the parenteral drug was to have been administered or at the time of discontinuation of a continuously administered parenteral drug (e.g., intravenous unfractionated heparin).</p>    <p> <a name="p1301122"></a>For patients currently taking PRADAXA, wait 12 hours (CrCl ≥30 mL/min) or 24 hours (CrCl &lt;30 mL/min) after the last dose of PRADAXA before initiating treatment with a parenteral anticoagulant <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.6"></a>   <a name="section-2.6"></a>    <p></p>    <h2>2.6 Discontinuation for Surgery and Other Interventions</h2>    <p class="First"> <a name="p1319122"></a>If possible, discontinue PRADAXA 1 to 2 days (CrCl ≥50 mL/min) or 3 to 5 days (CrCl &lt;50 mL/min) before invasive or surgical procedures because of the increased risk of bleeding. Consider longer times for patients undergoing major surgery, spinal puncture, or placement of a spinal or epidural catheter or port, in whom complete hemostasis may be required <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#Section_8.6">(8.6)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>    <p> <a name="p1542122"></a>If surgery cannot be delayed, there is an increased risk of bleeding <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.2">(5.2)</a>]</span></span>. This risk of bleeding should be weighed against the urgency of intervention <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1</a>, <a href="#Section_5.3">5.3)</a>]</span></span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3  DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="Section_3"></a>  <a name="section-3"></a>   <p></p>    <p class="First"> <a name="p1572122"></a>150 mg capsules with a light blue opaque cap imprinted in black with the Boehringer Ingelheim company symbol and a cream-colored opaque body imprinted in black with &quot;R150&quot;.</p>   <p> <a name="p1575122"></a>75 mg capsules with a cream-colored opaque cap imprinted in black with the Boehringer Ingelheim company symbol and a cream-colored opaque body imprinted in black with &quot;R75&quot;.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4  CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="Section_4"></a>  <a name="section-4"></a>   <p></p>    <p class="First"> <a name="p1797122"></a>PRADAXA is contraindicated in patients with:</p>   <ul class="Disc">    <li>Active pathological bleeding <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.2">(5.2)</a> and Adverse Reactions <a href="#Section_6.1">(6.1)</a>]</span></span>.</li>    <li>History of a serious hypersensitivity reaction to PRADAXA (e.g., anaphylactic reaction or anaphylactic shock) <span class="Italics"><span class="Emphasis">[see Adverse Reactions <a href="#Section_6.1">(6.1)</a>]</span></span>.</li>    <li>Mechanical prosthetic heart valve <span class="Italics">[see Warnings and Precautions <a href="#Section_5.4">(5.4)</a>]</span> </li>   </ul>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5  WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="Section_5"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.1"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Increased Risk of Thrombotic Events after Premature Discontinuation</h2>    <p class="First" style="border-left:1px solid;"> <a name="p179646221359037566"></a><span class="XmChange">Premature discontinuation of any oral anticoagulant, including PRADAXA, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see Dosage and Administration <a href="#Section_2.4">(2.4</a>, <a href="#Section_2.5">2.5</a>, <a href="#Section_2.6">2.6)</a>].</span></span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.2"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Risk of Bleeding</h2>    <p class="First"> <a name="p2086122"></a>PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding <span class="Italics"><span class="Emphasis">[see Dosage and Administration <a href="#Section_2.2">(2.2)</a>]</span></span>.</p>    <p> <a name="p2307122"></a>Risk factors for bleeding include the concomitant use of other drugs that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA’s anticoagulant activity and half-life are increased in patients with renal impairment <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.2">(12.2)</a>]</span></span>.</p>    <p> <a name="p2322122"></a><span class="Italics">Reversal of Anticoagulant Effect:</span> <br />A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however the clinical experience supporting the use of hemodialysis as a treatment for bleeding is limited <span class="Italics">[see Overdosage <a href="#Section_10">(10)</a>]</span>. Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. Consider administration of platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet drugs have been used.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.3"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Spinal/Epidural Anesthesia or Puncture</h2>    <p class="First" style="border-left:1px solid;"> <a name="p2332122"></a><span class="XmChange">When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis <span class="Italics">[see <a href="#Section_00">Boxed Warning</a>]</span>.</span> </p>    <p style="border-left:1px solid;"> <a name="p258578221355507317"></a><span class="XmChange">To reduce the potential risk of bleeding associated with the concurrent use of dabigatran and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of dabigatran <span class="Italics">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of dabigatran is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.</span> </p>    <p style="border-left:1px solid;"> <a name="p287054281396889747"></a><span class="XmChange">Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), bowel and/or bladder dysfunction. Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.4"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves</h2>    <p class="First"> <a name="p287096281396889825"></a>The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose adjusted warfarin or 150, 220, or 300 mg of PRADAXA twice a day. RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm. These bleeding and thromboembolic events were seen both in patients who were initiated on PRADAXA post-operatively within three days of mechanical bileaflet valve implantation, as well as in patients whose valves had been implanted more than three months prior to enrollment. Therefore, the use of PRADAXA is contraindicated in patients with mechanical prosthetic valves<span class="Italics"> [see Contraindications <a href="#Section_4">(4)</a>].</span> </p>    <p> <a name="p289406281396889861"></a>The use of PRADAXA for the prophylaxis of thromboembolic events in patients with atrial fibrillation in the setting of other forms of valvular heart disease, including the presence of a bioprosthetic heart valve, has not been studied and is not recommended.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.5"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure</h2>    <p class="First"> <a name="p2342122"></a>The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided <span class="Italics">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>.</p>    <p> <a name="p2561122"></a>P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran <span class="Italics">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>].</span> Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.</p>    <p style="border-left:1px solid;"> <a name="p2576122"></a><span class="XmChange"><span class="Italics"><span class="Underline">Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</span></span></span> </p>    <p> <a name="p30733281396889998"></a>Consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA in patients with moderate renal impairment (CrCl 30-50 mL/min). Avoid use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) <span class="Italics">[see Drug Interactions <a href="#Section_7.1">(7.1)</a> and Use in Specific Populations <a href="#Section_8.6">(8.6)</a>]</span>.</p>    <p style="border-left:1px solid;"> <a name="p28484281396890033"></a><span class="XmChange"><span class="Italics"><span class="Underline">Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</span></span></span> </p>    <p style="border-left:1px solid;"> <a name="p2894510281396890036"></a><span class="XmChange">Avoid use of PRADAXA and concomitant P-gp inhibitors in patients with CrCl &lt;50 mL/min <span class="Italics">[see Drug Interactions <a href="#Section_7.2">(7.2)</a> and Use in Specific Populations <a href="#Section_8.6">(8.6)</a>]</span>.</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6  ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="Section_6"></a>  <a name="section-6"></a>   <p></p>    <p class="First"> <a name="p2896910281396890210"></a>The most serious adverse reactions reported with PRADAXA were related to bleeding <span class="Italics">[see Warnings and Precautions <a href="#Section_5.2">(5.2)</a>]</span>.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_6.1"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Trials Experience</h2>    <p class="First"> <a name="p2835122"></a>Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>    <p> <a name="p291985281396890356"></a><span class="Italics"><span class="Underline">Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</span></span> </p>    <p> <a name="p2838122"></a>The RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) study provided safety information on the use of two doses of PRADAXA and warfarin <span class="Italics">[see Clinical Studies <a href="#Section_14.1">(14.1)</a>]</span>. The numbers of patients and their exposures are described in Table 1. Limited information is presented on the 110 mg dosing arm because this dose is not approved.</p>    <a name="t2851122"></a>    <div class="scrollingtable">    <table border="1" cellpadding="2" cellspacing="1" width="75%">      <caption>       <span>Table 1 Summary of Treatment Exposure in RE-LY</span>      </caption>      <colgroup>       <col width="7%" />       <col />       <col align="center" width="25%" />       <col align="center" width="25%" />       <col align="center" width="25%" />      </colgroup>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">PRADAXA 110 mg twice daily</span></span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">PRADAXA 150 mg twice daily</span></span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Warfarin</span></span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2">Total number treated</td>       <td class="Botrule Lrule Rrule Toprule" align="center">5983</td>       <td class="Botrule Lrule Rrule Toprule" align="center">6059</td>       <td class="Botrule Lrule Rrule Toprule" align="center">5998</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2">Exposure</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">&gt; 12 months</td>       <td class="Botrule Lrule Rrule Toprule" align="center">4936</td>       <td class="Botrule Lrule Rrule Toprule" align="center">4939</td>       <td class="Botrule Lrule Rrule Toprule" align="center">5193</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">&gt; 24 months</td>       <td class="Botrule Lrule Rrule Toprule" align="center">2387</td>       <td class="Botrule Lrule Rrule Toprule" align="center">2405</td>       <td class="Botrule Lrule Rrule Toprule" align="center">2470</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2">Mean exposure (months)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">20.5</td>       <td class="Botrule Lrule Rrule Toprule" align="center">20.3 </td>       <td class="Botrule Lrule Rrule Toprule" align="center">21.3 </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule Toprule" colspan="2">Total patient-years</td>       <td class="Botrule Lrule Rrule Toprule" align="center">10,242</td>       <td class="Botrule Lrule Rrule Toprule" align="center">10,261</td>       <td class="Botrule Lrule Rrule Toprule" align="center">10,659</td>       </tr>      </tbody>     </table>   </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_6.1.1"></a>    <a name="section-6.1.1"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p3597122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Drug Discontinuation in RE-LY</span></span></span> </p>     <p> <a name="p3606122"></a>The rates of adverse reactions leading to treatment discontinuation were 21% for PRADAXA 150 mg and 16% for warfarin. The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_6.1.2"></a>    <a name="section-6.1.2"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p3613122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Bleeding</span></span></span><span class="Italics"><span class="Emphasis"> [see Warnings and Precautions <a href="#Section_5.2">(5.2)</a>]</span></span> </p>     <p> <a name="p3631122"></a>Table 2 shows the number of patients experiencing serious bleeding during the treatment period in the RE-LY study, with the bleeding rate per 100 patient-years (%). Major bleeds fulfilled one or more of the following criteria: bleeding associated with a reduction in hemoglobin of at least 2 grams per deciliter or leading to a transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding). A life-threatening bleed met one or more of the following criteria: fatal, symptomatic intracranial bleed, reduction in hemoglobin of at least 5 grams per deciliter, transfusion of at least 4 units of blood, associated with hypotension requiring the use of intravenous inotropic agents, or necessitating surgical intervention. Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.</p>     <a name="t3840122"></a>     <div class="scrollingtable">     <table border="0" cellpadding="2" cellspacing="1" width="75%">       <caption>        <span>Table 2 Bleeding Events* (per 100 Patient-Years)</span>       </caption>       <colgroup>        <col width="25%" />        <col align="center" width="25%" />        <col align="center" width="25%" />        <col align="center" width="25%" />       </colgroup>       <tfoot>        <tr class="First Last">         <td colspan="4">* &nbsp;Patients contributed multiple events and events were counted in multiple categories.<br />** Confidence interval</td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">PRADAXA <br />150 mg twice daily<br />N&nbsp;(%)</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Warfarin<br />N&nbsp;(%)</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Hazard Ratio<br />(95% CI**)</span></span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule">Randomized patients</td>        <td class="Botrule Lrule Rrule Toprule" align="center">6076</td>        <td class="Botrule Lrule Rrule Toprule" align="center">6022</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule">Patient-years</td>        <td class="Botrule Lrule Rrule Toprule" align="center">12,033</td>        <td class="Botrule Lrule Rrule Toprule" align="center">11,794</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;Intracranial hemorrhage</td>        <td class="Botrule Lrule Rrule Toprule" align="center">39 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">91 (0.8)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.42 (0.29, 0.61)</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;Life-threatening bleed</td>        <td class="Botrule Lrule Rrule Toprule" align="center">183 (1.5)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">221 (1.9)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.81 (0.67, 0.99)</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;Major bleed</td>        <td class="Botrule Lrule Rrule Toprule" align="center">409 (3.4)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">426 (3.6)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.94 (0.82, 1.08) </td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;Any bleed</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1997 (16.6)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2169 (18.4)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.91 (0.85, 0.96)</td>        </tr>       </tbody>      </table>    </div>     <p> <a name="p4394122"></a>The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics, with the exception of age, where there was a trend towards a higher incidence of major bleeding on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.4) for patients ≥75 years of age.</p>     <p> <a name="p4397122"></a>There was a higher rate of major gastrointestinal bleeds in patients receiving PRADAXA 150 mg than in patients receiving warfarin (1.6% vs. 1.1%, respectively, with a hazard ratio vs. warfarin of 1.5, 95% CI, 1.2 to 1.9), and a higher rate of any gastrointestinal bleeds (5.7% vs. 3.9%, respectively).</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_6.1.3"></a>    <a name="section-6.1.3"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p4610122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Gastrointestinal Adverse Reactions</span></span></span> </p>     <p> <a name="p4619122"></a>Patients on PRADAXA 150 mg had an increased incidence of gastrointestinal adverse reactions (35% vs. 24% on warfarin). These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_6.1.4"></a>    <a name="section-6.1.4"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p4626122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Hypersensitivity Reactions</span></span></span> </p>     <p> <a name="p4635122"></a>In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in &lt;0.1% of patients receiving PRADAXA.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_6.1.5"></a>    <a name="section-6.1.5"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p245956281396890876"></a><span class="Italics"><span class="Underline">Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</span></span> </p>     <p> <a name="p292122281396890883"></a>PRADAXA was studied in 4387 patients in 4 pivotal, parallel, randomized, double-blind trials. Three of these trials were active-controlled (warfarin) (RE-COVER, RE-COVER II, and RE-MEDY), and one study (RE-SONATE) was placebo-controlled. The demographic characteristics were similar among the 4 pivotal studies and between the treatment groups within these studies. Approximately 60% of the treated patients were male, with a mean age of 55.1 years. The majority of the patients were white (87.7%), 10.3% were Asian, and 1.9% were black with a mean CrCl of 105.6 mL/min.</p>     <p> <a name="p292183281396890893"></a>Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).</p>     <p> <a name="p292222281396890895"></a>RE-COVER and RE-COVER II studies compared PRADAXA 150 mg twice daily and warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Patients received 5-10 days of an approved parenteral anticoagulant therapy followed by 6 months, with mean exposure of 164 days, of oral only treatment; warfarin was overlapped with parenteral therapy. Table 3 shows the number of patients experiencing bleeding events in the pooled analysis of RE-COVER and RE-COVER II studies during the full treatment including parenteral and oral only treatment periods after randomization.</p>     <a name="t22798328"></a>     <div class="scrollingtable">     <table border="0" frame="void" rules="none" width="75%">       <caption>        <span>Table 3 Bleeding Events in RE-COVER and RE-COVER II Treated Patients</span>       </caption>       <colgroup>        <col width="2.5%" />        <col width="24*" />        <col align="center" width="24*" />        <col align="center" width="24*" />       </colgroup>       <colgroup>        <col align="center" width="24*" />       </colgroup>       <tfoot>        <tr class="First Last">         <td colspan="5">Note: MBE can belong to more than one criterion.<br /> <span class="Sup">a</span>Patients with at least one MBE.<br /> <span class="Sup">b</span>Bleeding site based on investigator assessment. Patients can have more than one site of bleeding.<br /> <span class="Sup">c</span>Confidence interval</td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Bleeding Events-Full Treatment Period<br />Including Parenteral Treatment</span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PRADAXA<br />150 mg twice daily<br />N (%)</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Warfarin<br />N (%)</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Hazard Ratio<br />(95% CI)<span class="Sup">c</span></span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Patients</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=2553</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=2554</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Major bleeding event<span class="Sup">a</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">37 (1.4)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">51 (2.0)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.73 (0.48, 1.11)</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule"> Fatal bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.04)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Bleeding in a critical area or organ</td>        <td class="Botrule Lrule Rrule Toprule" align="center">7 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">15 (0.6)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Fall in hemoglobin ≥2g/dL or transfusion ≥2 units of whole blood or packed red blood cells</td>        <td class="Botrule Lrule Rrule Toprule" align="center">32 (1.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">38 (1.5)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Bleeding sites for MBE<span class="Sup">b</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Intracranial</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">5 (0.2)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Retroperitoneal</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.04)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Intraarticular</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">4 (0.2)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Intramuscular</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">6 (0.2)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Gastrointestinal</td>        <td class="Botrule Lrule Rrule Toprule" align="center">15 (0.6)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">14 (0.5)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Urogenital</td>        <td class="Botrule Lrule Rrule Toprule" align="center">7 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">14 (0.5)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Other</td>        <td class="Botrule Lrule Rrule Toprule" align="center">8 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">8 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Clinically relevant non-major bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">101 (4.0)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">170 (6.7)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.58 (0.46, 0.75)</td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule Toprule" colspan="2">Any bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">411 (16.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">567 (22.7)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.70 (0.61, 0.79)</td>        </tr>       </tbody>      </table>    </div>     <p> <a name="p164325281396892605"></a>The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).</p>     <p> <a name="p164257281396892621"></a>The RE-MEDY and RE-SONATE studies provided safety information on the use of PRADAXA for the reduction in the risk of recurrence of deep vein thrombosis and pulmonary embolism.</p>     <p> <a name="p3100113281396892630"></a>RE-MEDY was an active-controlled study (warfarin) in which 1430 patients received PRADAXA 150 mg twice daily following 3 to 12 months of oral anticoagulant regimen. Patients in the treatment studies who rolled over into the RE-MEDY study had a combined treatment duration of up to more than 3 years, with mean exposure of 473 days. Table 4 shows the number of patients experiencing bleeding events in the study.</p>     <a name="t32553128"></a>     <div class="scrollingtable">     <table border="0" frame="void" rules="none" width="75%">       <caption>        <span>Table 4 Bleeding Events in RE-MEDY Treated Patients</span>       </caption>       <colgroup>        <col width="2.5%" />        <col width="24*" />        <col align="center" width="24*" />        <col align="center" width="24*" />       </colgroup>       <colgroup>        <col align="center" width="24*" />       </colgroup>       <tfoot>        <tr class="First Last">         <td colspan="5">Note: MBE can belong to more than one criterion.<br /> <span class="Sup">a</span>Patients with at least one MBE.<br /> <span class="Sup">b</span>Bleeding site based on investigator assessment. Patients can have more than one site of bleeding.<br /> <span class="Sup">c</span>Confidence interval</td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PRADAXA<br />150 mg twice daily<br />N (%)</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Warfarin<br />N (%)</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Hazard Ratio<br />(95% CI)<span class="Sup">c</span></span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Patients</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=1430</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=1426</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Major bleeding event<span class="Sup">a</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">13 (0.9)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">25 (1.8)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.54 (0.25, 1.16)</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule"> Fatal bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Bleeding in a critical area or organ</td>        <td class="Botrule Lrule Rrule Toprule" align="center">7 (0.5)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">11 (0.8)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Fall in hemoglobin ≥2g/dL or transfusion ≥2 units of whole blood or packed red blood cells</td>        <td class="Botrule Lrule Rrule Toprule" align="center">7 (0.5)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">16 (1.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Bleeding sites for MBE<span class="Sup">b</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Intracranial</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">4 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Intraocular</td>        <td class="Botrule Lrule Rrule Toprule" align="center">4 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Retroperitoneal</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Intraarticular</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Intramuscular</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">4 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Gastrointestinal</td>        <td class="Botrule Lrule Rrule Toprule" align="center">4 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">8 (0.6)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Urogenital</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Other</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">4 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Clinically relevant non-major bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">71 (5.0)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">125 (8.8)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.56 (0.42, 0.75)</td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule Toprule" colspan="2">Any bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">278 (19.4)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">373 (26.2)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0.71 (0.61, 0.83)</td>        </tr>       </tbody>      </table>    </div>     <p> <a name="p3252810281396893509"></a>In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).</p>     <p> <a name="p325584281396893524"></a>RE-SONATE was a placebo-controlled study in which 684 patients received PRADAXA 150 mg twice daily following 6 to 18 months of oral anticoagulant regimen. Patients in the treatment studies who rolled over into the RE-SONATE study had combined treatment duration up to 9 months, with mean exposure of 165 days. Table 5 shows the number of patients experiencing bleeding events in the study.</p>     <a name="t34313128"></a>     <div class="scrollingtable">     <table border="0" frame="void" rules="none" width="75%">       <caption>        <span>Table 5 Bleeding Events in RE-SONATE Treated Patients</span>       </caption>       <colgroup>        <col width="2.5%" />        <col width="24*" />        <col align="center" width="24*" />        <col align="center" width="24*" />       </colgroup>       <colgroup>        <col align="center" width="24*" />       </colgroup>       <tfoot>        <tr class="First Last">         <td colspan="5">Note: MBE can belong to more than one criterion.<br /> <span class="Sup">a</span>Patients with at least one MBE.<br /> <span class="Sup">b</span>Bleeding site based on investigator assessment. Patients can have more than one site of bleeding.<br /> <span class="Sup">c</span>Confidence interval</td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PRADAXA<br />150 mg twice daily<br />N (%)</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br />N (%)</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Hazard Ratio<br />(95% CI)<span class="Sup">c</span></span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Patients</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=684</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=659</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Major bleeding event<span class="Sup">a</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Bleeding in a critical area or organ</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Toprule">&nbsp;</td>        <td class="Botrule Rrule Toprule">Gastrointestinal<span class="Sup">b</span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.3)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">0</td>        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" colspan="2">Clinically relevant non-major bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">34 (5.0)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">13 (2.0)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2.54 (1.34, 4.82)</td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule Toprule" colspan="2">Any bleeding</td>        <td class="Botrule Lrule Rrule Toprule" align="center">72 (10.5)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">40 (6.1)</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1.77 (1.20, 2.61)</td>        </tr>       </tbody>      </table>    </div>     <p> <a name="p3408513281396893713"></a>In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).</p>     <p> <a name="p340496281396893803"></a><span class="Italics">Clinical Myocardial Infarction Events</span> <br />In the active-controlled VTE studies, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA [20 (0.66 per 100 patient-years)] than in those who received warfarin [5 (0.17 per 100 patient-years)]. In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].</p>     <p> <a name="p1614810281396893867"></a><span class="Italics">Gastrointestinal Adverse Reactions</span> <br />In the four pivotal studies, patients on PRADAXA 150 mg had a similar incidence of gastrointestinal adverse reactions (24.7% vs. 22.7% on warfarin). Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.</p>     <p> <a name="p340560281396893882"></a><span class="Italics">Hypersensitivity Reactions</span> <br />In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_6.2"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Postmarketing Experience</h2>    <p class="First"> <a name="p16667422"></a>The following adverse reactions have been identified during post approval use of PRADAXA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7  DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="Section_7"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_7.1"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</h2>    <p class="First"> <a name="p51683281396893983"></a>The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided <span class="Italics">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>.</p>    <p> <a name="p51635281396894003"></a>P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran <span class="Italics">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.</p>    <p> <a name="p256479281396894023"></a>In patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dose adjustment of PRADAXA. These results should not be extrapolated to other P-gp inhibitors <span class="Italics">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>, Use in Specific Populations <a href="#Section_8.6">(8.6)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>.</p>    <p> <a name="p51503281396894056"></a>The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided <span class="Italics">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>, Use in Specific Populations <a href="#Section_8.6">(8.6)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_7.2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</h2>    <p class="First"> <a name="p51416281396894079"></a>Avoid use of PRADAXA and P-gp inhibitors in patients with CrCl &lt;50 mL/min <span class="Italics">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>, Use in Specific Populations <a href="#Section_8.6">(8.6)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8  USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="Section_8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="Section_8.1"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="42228-7">     <a name="Section_8.1.1"></a>    <a name="section-8.1.1"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p5168122"></a><span class="Italics"><span class="Underline">Pregnancy Category C</span></span> </p>     <p> <a name="p5382122"></a>There are no adequate and well-controlled studies in pregnant women.</p>     <p> <a name="p5385122"></a>Dabigatran has been shown to decrease the number of implantations when male and female rats were treated at a dosage of 70 mg/kg (about 2.6 to 3.0 times the human exposure at maximum recommended human dose [MRHD] of 300 mg/day based on area under the curve [AUC] comparisons) prior to mating and up to implantation (gestation Day 6). Treatment of pregnant rats after implantation with dabigatran at the same dose increased the number of dead offspring and caused excess vaginal/uterine bleeding close to parturition. Although dabigatran increased the incidence of delayed or irregular ossification of fetal skull bones and vertebrae in the rat, it did not induce major malformations in rats or rabbits.</p>    </div>   </div>   <div class="Section" data-sectioncode="34079-4">    <a name="Section_8.2"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.2 Labor and Delivery</h2>    <p class="First"> <a name="p5393122"></a>Safety and effectiveness of PRADAXA during labor and delivery have not been studied in clinical trials. Consider the risks of bleeding and of stroke in using PRADAXA in this setting<span class="Italics"> [see Warnings and Precautions <a href="#Section_5.2">(5.2)</a>]</span>.</p>    <p> <a name="p5406122"></a>Death of offspring and mother rats during labor in association with uterine bleeding occurred during treatment of pregnant rats from implantation (gestation Day 7) to weaning (lactation Day 21) with dabigatran at a dose of 70 mg/kg (about 2.6 times the human exposure at MRHD of 300 mg/day based on AUC comparisons).</p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="Section_8.3"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First"> <a name="p5414122"></a>It is not known whether dabigatran is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from PRADAXA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="Section_8.4"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First"> <a name="p5422122"></a>Safety and effectiveness of PRADAXA in pediatric patients have not been established.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="Section_8.5"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First"> <a name="p5636122"></a>Of the total number of patients in the RE-LY study, 82% were 65 and over, while 40% were 75 and over. The risk of stroke and bleeding increases with age, but the risk-benefit profile is favorable in all age groups <span class="Italics">[see Warnings and Precautions <a href="#Section_5">(5)</a>, Adverse Reactions <a href="#Section_6.1">(6.1)</a>, and Clinical Studies <a href="#Section_14.1">(14.1)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_8.6"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.6 Renal Impairment</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_8.6.1"></a>    <a name="section-8.6.1"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p59232281396894465"></a><span class="Italics"><span class="Underline">Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</span></span> </p>     <p> <a name="p5662122"></a>No dose adjustment of PRADAXA is recommended in patients with mild or moderate renal impairment <span class="Italics">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>. Reduce the dose of PRADAXA in patients with severe renal impairment (CrCl 15-30 mL/min) <span class="Italics">[see Dosage and Administration <a href="#Section_2.1">(2.1</a>, <a href="#Section_2.2">2.2)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span>. Dosing recommendations for patients with CrCl &lt;15 mL/min or on dialysis cannot be provided.</p>     <p> <a name="p5899122"></a>Adjust dose appropriately in patients with renal impairment receiving concomitant P-gp inhibitors <span class="Italics">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>, Drug Interactions <a href="#Section_7.1">(7.1)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>].</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_8.6.2"></a>    <a name="section-8.6.2"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p592412281396894640"></a><span class="Italics"><span class="Underline">Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</span></span> </p>     <p> <a name="p3355010281396894651"></a>Patients with severe renal impairment (CrCl ≤30 mL/min) were excluded from RE-COVER.</p>     <p> <a name="p335593281396894660"></a>Dosing recommendations for patients with CrCl ≤30 mL/min or on dialysis cannot be provided. Avoid use of PRADAXA with concomitant P-gp inhibitors in patients with CrCl &lt;50 mL/min<span class="Italics"> [see Warnings and Precautions <a href="#Section_5.5">(5.5)</a>, Drug Interactions <a href="#Section_7.2">(7.2)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>].</span> </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10  OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="Section_10"></a>  <a name="section-9"></a>   <p></p>    <p class="First"> <a name="p5925122"></a>Accidental overdose may lead to hemorrhagic complications. There is no reversal agent for dabigatran. In the event of hemorrhagic complications, initiate appropriate clinical support, discontinue treatment with PRADAXA, and investigate the source of bleeding. Dabigatran is primarily eliminated by the kidneys with a low plasma protein binding of approximately 35%. Hemodialysis can remove dabigatran; however, data supporting this approach are limited. Using a high-flux dialyzer, blood flow rate of 200 mL/min, and dialysate flow rate of 700 mL/min, approximately 49% of total dabigatran can be cleared from plasma over 4 hours. At the same dialysate flow rate, approximately 57% can be cleared using a dialyzer blood flow rate of 300 mL/min, with no appreciable increase in clearance observed at higher blood flow rates. Upon cessation of hemodialysis, a redistribution effect of approximately 7% to 15% is seen. The effect of dialysis on dabigatran’s plasma concentration would be expected to vary based on patient specific characteristics. Measurement of aPTT or ECT may help guide therapy <span class="Italics">[see Warnings and Precautions <a href="#Section_5.2">(5.2)</a> and Clinical Pharmacology <a href="#Section_12.2">(12.2)</a>].</span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11  DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="Section_11"></a>  <a name="section-10"></a>   <p></p>    <p class="First"> <a name="p6152122"></a>The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is β-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate. The empirical formula is C<span class="Sub">34</span>H<span class="Sub">41</span>N<span class="Sub">7</span>O<span class="Sub">5 </span>⋅ CH<span class="Sub">4</span>O<span class="Sub">3</span>S and the molecular weight is 723.86 (mesylate salt), 627.75 (free base). The structural formula is:</p>   <p> <a name="p3715712281396970617"></a><img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=praxada%2Dstruct%2Ejpg" alt="Praxada (dabigatran etexilate mesylate) structure" /></p>   <p> <a name="p6181122"></a>Dabigatran etexilate mesylate is a yellow-white to yellow powder. A saturated solution in pure water has a solubility of 1.8 mg/mL. It is freely soluble in methanol, slightly soluble in ethanol, and sparingly soluble in isopropanol.</p>   <p> <a name="p6184122"></a>The 150 mg capsule for oral administration contains 172.95 mg dabigatran etexilate mesylate, which is equivalent to 150 mg of dabigatran etexilate, and the following inactive ingredients: acacia, dimethicone, hypromellose, hydroxypropyl cellulose, talc, and tartaric acid. The capsule shell is composed of carrageenan, FD&amp;C Blue No. 2 (150 mg only), FD&amp;C Yellow No. 6, hypromellose, potassium chloride, titanium dioxide, and black edible ink. The 75 mg capsule contains 86.48 mg dabigatran etexilate mesylate, equivalent to 75 mg dabigatran etexilate, and is otherwise similar to the 150 mg capsule.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12  CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="Section_12"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="Section_12.1"></a>   <a name="section-11.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First"> <a name="p6403122"></a>Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="Section_12.2"></a>   <a name="section-11.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First"> <a name="p6411122"></a>At recommended therapeutic doses, dabigatran etexilate prolongs the coagulation markers such as aPTT, ECT, and TT. INR is relatively insensitive to the exposure to dabigatran and cannot be interpreted the same way as used for warfarin monitoring.</p>    <p> <a name="p6414122"></a>The aPTT test provides an approximation of PRADAXA’s anticoagulant effect. The average time course for effects on aPTT, following approved dosing regimens in patients with various degrees of renal impairment is shown in Figure 1. The curves represent mean levels without confidence intervals; variations should be expected when measuring aPTT. While advice cannot be provided on the level of recovery of aPTT needed in any particular clinical setting, the curves can be used to estimate the time to get to a particular level of recovery, even when the time since the last dose of PRADAXA is not precisely known. In the RE-LY trial, the median (10<span class="Sup">th</span> to 90<span class="Sup">th</span> percentile) trough aPTT in patients receiving the 150 mg dose was 52 (40 to 76) seconds.</p>    <p> <a name="p6417122"></a><span class="ParagraphCaption">Figure 1 Average Time Course for Effects of Dabigatran on aPTT, Following Approved PRADAXA Dosing Regimens in Patients with Various Degrees of Renal Impairment*</span> </p>    <p> <a name="p6422122"></a><img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=figure%2D1%2Ejpg" alt="Average Time Course for Effects of Dabigatran on aPTT, Following Approved PRADAXA Dosing Regimens in Patients with Various Degrees of Renal Impairment*" /></p>    <p> <a name="p6426122"></a>*Simulations based on PK data from a study in subjects with renal impairment and PK/aPTT relationships derived from the RE-LY study; aPTT prolongation in RE-LY was measured centrally in citrate plasma using PTT Reagent Roche Diagnostics GmbH, Mannheim, Germany. There may be quantitative differences between various established methods for aPTT assessment.</p>    <p> <a name="p6429122"></a>The degree of anticoagulant activity can also be assessed by the ecarin clotting time (ECT). This test is a more specific measure of the effect of dabigatran than activated partial thromboplastin time (aPTT). In the RE-LY trial, the median (10<span class="Sup">th</span> to 90<span class="Sup">th</span> percentile) trough ECT in patients receiving the 150 mg dose was 63 (44 to 103) seconds.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.2.1"></a>    <a name="section-11.2.1"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p6444122"></a><span class="Italics"><span class="Underline">Cardiac Electrophysiology</span></span> </p>     <p> <a name="p6659122"></a>No prolongation of the QTc interval was observed with dabigatran etexilate at doses up to 600 mg.</p>    </div>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="Section_12.3"></a>   <a name="section-11.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First"> <a name="p6667122"></a>Dabigatran etexilate mesylate is absorbed as the dabigatran etexilate ester. The ester is then hydrolyzed, forming dabigatran, the active moiety. Dabigatran is metabolized to four different acyl glucuronides and both the glucuronides and dabigatran have similar pharmacological activity. Pharmacokinetics described here refer to the sum of dabigatran and its glucuronides. Dabigatran displays dose-proportional pharmacokinetics in healthy subjects and patients in the range of doses from 10 to 400 mg.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.1"></a>    <a name="section-11.3.1"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p6674122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Absorption</span></span></span> </p>     <p> <a name="p6683122"></a>The absolute bioavailability of dabigatran following oral administration of dabigatran etexilate is approximately 3 to 7%. Dabigatran etexilate is a substrate of the efflux transporter P-gp. After oral administration of dabigatran etexilate in healthy volunteers, C<span class="Sub">max</span> occurs at 1 hour post-administration in the fasted state. Coadministration of PRADAXA with a high-fat meal delays the time to C<span class="Sub">max</span> by approximately 2 hours but has no effect on the bioavailability of dabigatran; PRADAXA may be administered with or without food.</p>     <p> <a name="p6694122"></a>The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation. PRADAXA capsules should therefore not be broken, chewed, or opened before administration.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.2"></a>    <a name="section-11.3.2"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p6701122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Distribution</span></span></span> </p>     <p> <a name="p6916122"></a>Dabigatran is approximately 35% bound to human plasma proteins. The red blood cell to plasma partitioning of dabigatran measured as total radioactivity is less than 0.3. The volume of distribution of dabigatran is 50 to 70 L. Dabigatran pharmacokinetics are dose proportional after single doses of 10 to 400 mg. Given twice daily, dabigatran’s accumulation factor is approximately two.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.3"></a>    <a name="section-11.3.3"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p6923122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Elimination</span></span></span> </p>     <p> <a name="p6932122"></a>Dabigatran is eliminated primarily in the urine. Renal clearance of dabigatran is 80% of total clearance after intravenous administration. After oral administration of radiolabeled dabigatran, 7% of radioactivity is recovered in urine and 86% in feces. The half-life of dabigatran in healthy subjects is 12 to 17 hours.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.4"></a>    <a name="section-11.3.4"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p6939122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Metabolism</span></span></span> </p>     <p> <a name="p6948122"></a>After oral administration, dabigatran etexilate is converted to dabigatran. The cleavage of the dabigatran etexilate by esterase-catalyzed hydrolysis to the active principal dabigatran is the predominant metabolic reaction. Dabigatran is not a substrate, inhibitor, or inducer of CYP450 enzymes. Dabigatran is subject to conjugation forming pharmacologically active acyl glucuronides. Four positional isomers, 1-O, 2-O, 3-O, and 4-O-acylglucuronide exist, and each accounts for less than 10% of total dabigatran in plasma.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.5"></a>    <a name="section-11.3.5"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p6955122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Renal Impairment</span></span></span> </p>     <p> <a name="p7170122"></a>An open, parallel-group single-center study compared dabigatran pharmacokinetics in healthy subjects and patients with mild to moderate renal impairment receiving a single dose of PRADAXA 150 mg. Exposure to dabigatran increases with severity of renal function impairment (Table 6). Similar findings were observed in the RE-LY and RE-COVER trials.</p>     <a name="t7173122"></a>     <div class="scrollingtable">     <table border="0" cellpadding="2" cellspacing="1" width="75%">       <caption>        <span>Table 6 Impact of Renal Impairment on Dabigatran Pharmacokinetics</span>       </caption>       <colgroup>        <col align="center" width="19%" />        <col align="center" width="19%" />        <col align="center" width="20%" />        <col align="center" width="19%" />        <col align="center" width="20%" />       </colgroup>       <tfoot>        <tr class="First Last">         <td align="left" colspan="5"><span class="Sup">+</span>Patients with severe renal impairment were not studied in RE-LY and RE-COVER. Dosing recommendations in subjects with severe renal impairment are based on pharmacokinetic modeling <span class="Italics">[see Dosage and Administration <a href="#Section_2.1">(2.1</a>, <a href="#Section_2.2">2.2)</a> and Use in Specific Populations <a href="#Section_8.6">(8.6)</a>]</span>.</td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Renal Function</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">CrCl (mL/min)</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Increase in AUC</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Increase in C<span class="Sub">max</span></span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">t<span class="Sub">1/2</span> <br />(h)</span></span></td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Normal</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">≥ 80</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">13</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Mild</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">50-80</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1.5x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1.1x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">15</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Moderate</span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">30-50</td>        <td class="Botrule Lrule Rrule Toprule" align="center">3.2x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">1.7x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">18</td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Severe<span class="Sup">+</span></span></span></td>        <td class="Botrule Lrule Rrule Toprule" align="center">15-30</td>        <td class="Botrule Lrule Rrule Toprule" align="center">6.3x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">2.1x</td>        <td class="Botrule Lrule Rrule Toprule" align="center">27</td>        </tr>       </tbody>      </table>    </div>     <p> <a name="p7963122"></a> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.6"></a>    <a name="section-11.3.6"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p7969122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Hepatic Impairment</span></span></span> </p>     <p> <a name="p7978122"></a>Administration of PRADAXA in patients with moderate hepatic impairment (Child-Pugh B) showed a large inter-subject variability, but no evidence of a consistent change in exposure or pharmacodynamics.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.7"></a>    <a name="section-11.3.7"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p7985122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Drug Interactions</span></span></span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.8"></a>    <a name="section-11.3.8"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p22577622"></a><span class="Italics"><span class="Emphasis">Impact of Other Drugs on Dabigatran</span></span> <br /> <span class="Underline">P-gp Inducers</span> </p>     <p> <a name="p8212122"></a><span class="Italics">Rifampin: </span>Rifampin 600 mg once daily for 7 days followed by a single dose of dabigatran decreased its AUC and C<span class="Sub">max</span> by 66% and 67%, respectively. By Day 7 after cessation of rifampin treatment, dabigatran exposure was close to normal <span class="Italics">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a> and Drug Interactions <a href="#Section_7">(7)</a>]</span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.9"></a>    <a name="section-11.3.9"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p24878122"></a><span class="Underline">P-gp Inhibitors</span> </p>     <p> <a name="p8449122"></a>In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. Any observed changes in C<span class="Sub">max </span>and AUC are described below.</p>     <p> <a name="p8456122"></a><span class="Italics">Dronedarone:</span> Simultaneous administration of dabigatran etexilate and dronedarone (administered once or twice daily) increases exposure to dabigatran by 70 to 140% compared to dabigatran alone. The increase in exposure is only 30 to 60% higher compared to dabigatran alone when dronedarone is administered 2 hours after dabigatran etexilate.</p>     <p> <a name="p8464122"></a><span class="Italics">Ketoconazole</span>: Systemic ketoconazole increased dabigatran AUC and C<span class="Sub">max</span> values by 138% and 135%, respectively, after a single dose of 400 mg, and 153%, and 149%, respectively, after multiple daily doses of 400 mg.</p>     <p> <a name="p8476122"></a><span class="Italics">Verapamil</span>: When dabigatran etexilate was coadministered with oral verapamil, the C<span class="Sub">max </span>and AUC of dabigatran were increased. The extent of increase depends on the formulation of verapamil and timing of administration. If verapamil is present in the gut when dabigatran is taken, it will increase exposure to dabigatran with the greatest increase observed when a single dose of immediate-release verapamil is given one hour prior to dabigatran (AUC increased by a factor of 2.4). If verapamil is given 2 hours after dabigatran, the increase in AUC is negligible. In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received verapamil. Similar findings were observed in the RE-COVER study.</p>     <p> <a name="p8488122"></a><span class="Italics">Amiodarone</span>: When dabigatran etexilate was coadministered with a single 600 mg oral dose of amiodarone, the dabigatran AUC and C<span class="Sub">max</span> increased by 58% and 50%, respectively. The increase in exposure was mitigated by a 65% increase in the renal clearance of dabigatran in the presence of amiodarone. The increase in renal clearance may persist after amiodarone is discontinued because of amiodarone’s long half-life. In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received amiodarone.</p>     <p> <a name="p8706122"></a><span class="Italics">Quinidine</span>: Quinidine was given as a 200 mg dose every 2 hours up to a total dose of 1000 mg. Dabigatran etexilate was given over 3 consecutive days, the last evening dose on Day 3 with or without quinidine pre-dosing. Concomitant quinidine administration increased dabigatran’s AUC and C<span class="Sub">max</span> by 53% and 56%, respectively.</p>     <p> <a name="p8718122"></a><span class="Italics">Clarithromycin:</span> Coadministered clarithromycin had no impact on the exposure to dabigatran.</p>     <p> <a name="p163923281408117503"></a><span class="Italics">Ticagrelor:</span> Administration of ticagrelor modestly increases plasma concentrations of dabigatran with the magnitude of increase dependent on the dose and timing of ticagrelor administration. When dabigatran etexilate 110 mg twice daily was coadministered with 90 mg oral ticagrelor twice daily, the AUC<span class="Sub">τ,ss</span> and C<span class="Sub">max,ss</span> of dabigatran increased by 26% and 29%, respectively. When coadministered with a loading dose of 180 mg ticagrelor, the AUC<span class="Sub">τ,ss</span> and C<span class="Sub">max,ss</span> of dabigatran increased by 49% and 65%, respectively; but when ticagrelor 180 mg was given 2 hours after dabigatran, the AUC<span class="Sub">τ,ss</span> and C<span class="Sub">max,ss</span> of dabigatran increased by only 27% and 24%, respectively <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.2">5.2</a>) and Drug Interactions (<a href="#Section_7.1">7.1</a>)]</span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="Section_12.3.10"></a>    <a name="section-11.3.10"></a>     <p></p>     <h3></h3>     <p class="First"> <a name="p25095122"></a><span class="Underline">Other Drugs</span> </p>     <p> <a name="p8731122"></a><span class="Italics">Clopidogrel</span>: When dabigatran etexilate was given concomitantly with a loading dose of 300 mg or 600 mg clopidogrel, the dabigatran AUC and C<span class="Sub">max</span> increased by approximately 30% and 40%, respectively. The concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy. When comparing combined treatment and the respective mono-treatments, the coagulation measures for dabigatran’s effect (aPTT, ECT, and TT) remained unchanged, and inhibition of platelet aggregation (IPA), a measurement of clopidogrel’s effect, remained unchanged.</p>     <p> <a name="p8743122"></a><span class="Italics">Enoxaparin: </span> Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT.</p>     <p> <a name="p8751122"></a><span class="Italics"><span class="Emphasis">Diclofenac, Ranitidine, and Digoxin:</span></span> None of these drugs alters exposure to dabigatran.</p>     <p> <a name="p8965122"></a>In RE-LY, dabigatran plasma samples were also collected. The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.</p>     <p> <a name="p94934281396895954"></a><span class="Italics">Impact of Dabigatran on Other Drugs</span> <br />In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13  NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="Section_13"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="Section_13.1"></a>   <a name="section-12.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <p class="First"> <a name="p8992122"></a>Dabigatran was not carcinogenic when administered by oral gavage to mice and rats for up to 2 years. The highest doses tested (200 mg/kg/day) in mice and rats were approximately 3.6 and 6 times, respectively, the human exposure at MRHD of 300 mg/day based on AUC comparisons.</p>    <p> <a name="p8995122"></a>Dabigatran was not mutagenic in <span class="Italics">in vitro </span>tests, including bacterial reversion tests, mouse lymphoma assay and chromosomal aberration assay in human lymphocytes, and the <span class="Italics">in vivo </span>micronucleus assay in rats.</p>    <p> <a name="p9216122"></a>In the rat fertility study with oral gavage doses of 15, 70, and 200 mg/kg, males were treated for 29 days prior to mating, during mating up to scheduled termination, and females were treated 15 days prior to mating through gestation Day 6. No adverse effects on male or female fertility were observed at 200 mg/kg or 9 to 12 times the human exposure at MRHD of 300 mg/day based on AUC comparisons. However, the number of implantations decreased in females receiving 70 mg/kg, or 3 times the human exposure at MRHD based on AUC comparisons.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14  CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="Section_14"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_14.1"></a>   <a name="section-13.1"></a>    <p></p>    <h2>14.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</h2>    <p class="First"> <a name="p9224122"></a>The clinical evidence for the efficacy of PRADAXA was derived from RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy), a multi-center, multi-national, randomized parallel group trial comparing two blinded doses of PRADAXA (110 mg twice daily and 150 mg twice daily) with open-label warfarin (dosed to target INR of 2 to 3) in patients with non-valvular, persistent, paroxysmal, or permanent atrial fibrillation and one or more of the following additional risk factors:</p>    <ul class="Disc">     <li>Previous stroke, transient ischemic attack (TIA), or systemic embolism</li>     <li>Left ventricular ejection fraction &lt;40% </li>     <li>Symptomatic heart failure, ≥ New York Heart Association Class 2</li>     <li>Age ≥75 years</li>     <li>Age ≥65 years and one of the following: diabetes mellitus, coronary artery disease (CAD), or hypertension </li>    </ul>    <p> <a name="p9244122"></a>The primary objective of this study was to determine if PRADAXA was non-inferior to warfarin in reducing the occurrence of the composite endpoint, stroke (ischemic and hemorrhagic) and systemic embolism. The study was designed to ensure that PRADAXA preserved more than 50% of warfarin’s effect as established by previous randomized, placebo-controlled trials of warfarin in atrial fibrillation. Statistical superiority was also analyzed.</p>    <p> <a name="p9247122"></a>A total of 18,113 patients were randomized and followed for a median of 2 years. The patients’ mean age was 71.5 years and the mean CHADS<span class="Sub">2</span> score was 2.1. The patient population was 64% male, 70% Caucasian, 16% Asian, and 1% black. Twenty percent of patients had a history of a stroke or TIA and 50% were Vitamin K antagonist (VKA) na&iuml;ve, defined as less than 2 months total lifetime exposure to a VKA. Thirty-two percent of the population had never been exposed to a VKA. Concomitant diseases of patients in this trial included hypertension 79%, diabetes 23%, and CAD 28%. At baseline, 40% of patients were on aspirin and 6% were on clopidogrel. For patients randomized to warfarin, the mean percentage of time in therapeutic range (INR 2 to 3) was 64%.</p>    <p> <a name="p9254122"></a>Relative to warfarin and to PRADAXA 110 mg twice daily, PRADAXA 150 mg twice daily significantly reduced the primary composite endpoint of stroke and systemic embolism (see Table 7 and Figure 2).</p>    <a name="t9257122"></a>    <div class="scrollingtable">    <table border="1" cellpadding="2" cellspacing="1" width="75%">      <caption>       <span>Table 7 First Occurrence of Stroke or Systemic Embolism in the RE-LY Study</span>      </caption>      <colgroup>       <col width="40%" />       <col align="center" width="20%" />       <col align="center" width="20%" />       <col align="center" width="20%" />      </colgroup>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">PRADAXA <br />150 mg twice daily</span></span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">PRADAXA <br />110 mg twice daily</span></span></td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><span class="Emphasis">Warfarin</span></span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">Patients randomized</td>       <td class="Botrule Lrule Rrule Toprule" align="center">6076</td>       <td class="Botrule Lrule Rrule Toprule" align="center">6015</td>       <td class="Botrule Lrule Rrule Toprule" align="center">6022</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">Patients (%) with events </td>       <td class="Botrule Lrule Rrule Toprule" align="center">135 (2.2%)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">183 (3%)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">203 (3.4%)</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">Hazard ratio vs. warfarin (95% CI)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.65 (0.52, 0.81)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.89 (0.73, 1.09)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;P-value for superiority</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.0001</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.27</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">Hazard ratio vs. PRADAXA 110 mg (95% CI)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.72 (0.58, 0.91)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;P-value for superiority</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.005</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>      </tbody>     </table>   </div>    <p> <a name="p10004122"></a><span class="ParagraphCaption">Figure 2 Kaplan-Meier Curve Estimate of Time to First Stroke or Systemic Embolism</span> </p>    <p> <a name="p10009122"></a><img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=figure%2D2%2Ejpg" alt="Kaplan-Meier Curve Estimate of Time to First Stroke or Systemic Embolism" /></p>    <p> <a name="p10013122"></a>The contributions of the components of the composite endpoint, including stroke by subtype, are shown in Table 8. The treatment effect was primarily a reduction in stroke. PRADAXA 150 mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin.</p>    <a name="t10016122"></a>    <div class="scrollingtable">    <table border="1" cellpadding="0" cellspacing="0" width="75%">      <caption>       <span>Table 8 Strokes and Systemic Embolism in the RE-LY Study</span>      </caption>      <colgroup>       <col width="25%" />       <col align="center" width="25%" />       <col align="center" width="30%" />       <col align="center" width="20%" />      </colgroup>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><span class="Emphasis">PRADAXA<br />150 mg twice daily</span></span></td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><span class="Emphasis">Warfarin </span></span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Hazard ratio vs. warfarin</span></span> <br /> <span class="Bold"><span class="Emphasis">(95% CI) </span></span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">Patients randomized</td>       <td class="Botrule Lrule Rrule Toprule" align="center">6076</td>       <td class="Botrule Lrule Rrule Toprule" align="center">6022</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">Stroke </td>       <td class="Botrule Lrule Rrule Toprule" align="center">123 </td>       <td class="Botrule Lrule Rrule Toprule" align="center">187 </td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.64 (0.51, 0.81)</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;Ischemic stroke</td>       <td class="Botrule Lrule Rrule Toprule" align="center">104</td>       <td class="Botrule Lrule Rrule Toprule" align="center">134</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.76 (0.59, 0.98)</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule">&nbsp;&nbsp;&nbsp;Hemorrhagic stroke</td>       <td class="Botrule Lrule Rrule Toprule" align="center">12</td>       <td class="Botrule Lrule Rrule Toprule" align="center">45</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.26 (0.14, 0.49)</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule Toprule">Systemic embolism</td>       <td class="Botrule Lrule Rrule Toprule" align="center">13</td>       <td class="Botrule Lrule Rrule Toprule" align="center">21</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.61 (0.30, 1.21)</td>       </tr>      </tbody>     </table>   </div>    <p> <a name="p2615310221358779343"></a>In the RE-LY trial, the rate of all-cause mortality was lower on dabigatran 150 mg than on warfarin (3.6% per year versus 4.1% per year). The rate of vascular death was lower on dabigatran 150 mg compared to warfarin (2.3% per year versus 2.7% per year). Non-vascular death rates were similar in the treatment arms.</p>    <p> <a name="p10757122"></a>The efficacy of PRADAXA 150 mg twice daily was generally consistent across major subgroups (see Figure 3).</p>    <p> <a name="p10760122"></a><span class="ParagraphCaption">Figure 3 Stroke and Systemic Embolism Hazard Ratios by Baseline Characteristics</span> </p>    <p> <a name="p10765122"></a><img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=figure%2D3%2Ejpg" alt="Stroke and Systemic Embolism Hazard Ratios by Baseline Characteristics" /></p>    <p> <a name="p11048122"></a>In RE-LY, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA (0.7 per 100 patient-years for 150 mg dose) than in those who received warfarin (0.6).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_14.2"></a>   <a name="section-13.2"></a>    <p></p>    <h2>14.2 Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</h2>    <p class="First"> <a name="p353724281396899052"></a>In the randomized, parallel group, double-blind trials, RE-COVER and RE-COVER II, patients with deep vein thrombosis and pulmonary embolism received PRADAXA 150 mg twice daily or warfarin (dosed to target INR of 2 to 3) following initial treatment with an approved parenteral anticoagulant for 5-10 days.</p>    <p> <a name="p353693281396899060"></a>In RE-COVER, the median treatment duration during the oral only treatment period was 174 days. A total of 2539 patients (30.9% patients with symptomatic PE with or without DVT and 68.9% with symptomatic DVT only) were treated with a mean age of 54.7 years. The patient population was 58.4% male, 94.8% white, 2.6% Asian, and 2.6% black. The concomitant diseases of patients in this trial included hypertension (35.9%), diabetes mellitus (8.3%), coronary artery disease (6.5%), active cancer (4.8%), and gastric or duodenal ulcer (4.4%). Concomitant medications included agents acting on renin-angiotensin system (25.2%), vasodilators (28.4%), serum lipid-reducing agents (18.2%), NSAIDs (21%), beta-blockers (14.8%), calcium channel blockers (8.5%), ASA (8.6%), and platelet inhibitors excluding ASA (0.6%). Patients randomized to warfarin had a mean percentage of time in the INR target range of 2.0 to 3.0 of 60% in RE-COVER study.</p>    <p> <a name="p353663281396899069"></a>In RE-COVER II, the median treatment duration during the oral only treatment period was 174 days. A total of 2568 patients (31.8% patients with symptomatic PE with or without DVT and 68.1% with symptomatic DVT only) were treated with a mean age of 54.9 years. The patient population was 60.6% male, 77.6% white, 20.9% Asian, and 1.5% black. The concomitant diseases of patients in this trial included hypertension (35.1%), diabetes mellitus (9.8%), coronary artery disease (7.1%), active cancer (3.9%), and gastric or duodenal ulcer (3.8%). Concomitant medications included agents acting on renin-angiotensin system (24.2%), vasodilators (28.6%), serum lipid-reducing agents (20.0%), NSAIDs (22.3%), beta-blockers (14.8%), calcium channel blockers (10.8%), ASA (9.8%), and platelet inhibitors excluding ASA (0.8%). Patients randomized to warfarin had a mean percentage of time in the INR target range of 2.0 to 3.0 of 57% in RE-COVER II study.</p>    <p> <a name="p353633281396899082"></a>In studies RE-COVER and RE-COVER II, the protocol specified non-inferiority margin (2.75) for the hazard ratio was derived based on the upper limit of the 95% confidence interval of the historical warfarin effect. PRADAXA was demonstrated to be non-inferior to warfarin (dosed to target INR of 2 to 3) (Table 9) based on the primary composite endpoint (fatal PE or symptomatic non-fatal PE and/or DVT) and retains at least 66.9% (RE-COVER) and 63.9% (RE-COVER II)&nbsp;of the historical warfarin effect respectively.</p>    <a name="t35359328"></a>    <div class="scrollingtable">    <table border="0" frame="void" rules="none" width="75%">      <caption>       <span>Table 9 Primary Efficacy Endpoint for RE-COVER and RE-COVER II – Modified ITT<span class="Sup">a</span> Population</span>      </caption>      <colgroup>       <col width="2.5%" />       <col width="24*" />       <col align="center" width="24*" />       <col align="center" width="24*" />      </colgroup>      <colgroup>       <col align="center" width="24*" />      </colgroup>      <tfoot>       <tr class="First Last">        <td colspan="5"><span class="Sup">a</span>Modified ITT analyses population consists of all randomized patients who received at least one dose of study medication.<br /> <span class="Sup">b</span>Number of patients with one or more event.<br /> <span class="Sup">c</span>Number of events. For patients with multiple events each event is counted independently.</td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PRADAXA<br />150 mg twice daily<br />N (%)</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Warfarin<br />N (%)</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Hazard ratio vs.<br />warfarin (95% CI)</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">RE-COVER</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=1274</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=1265</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2">Primary Composite Endpoint<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">34 (2.7)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">32 (2.5)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">1.05 (0.65, 1.70)</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Fatal PE<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.1)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">3 (0.2)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic non-fatal PE<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">16 (1.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">8 (0.6)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic recurrent DVT<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">17 (1.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">23 (1.8)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">RE-COVER II</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=1279</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N=1289</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2">Primary Composite Endpoint<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">34 (2.7)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">30 (2.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">1.13 (0.69, 1.85)</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Fatal PE<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">3 (0.2)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic non-fatal PE<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">9 (0.7)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">15 (1.2)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic recurrent DVT<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">30 (2.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">17 (1.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>      </tbody>     </table>   </div>    <p> <a name="p3482313281396899671"></a>In the randomized, parallel group, double-blind, pivotal trial, RE-MEDY, patients received PRADAXA 150 mg twice daily or warfarin (dosed to target INR of 2 to 3) following 3 to 12 months of treatment with anticoagulation therapy for an acute VTE. The median treatment duration during the treatment period was 534 days. A total of 2856 patients were treated with a mean age of 54.6 years. The patient population was 61% male, and 90.1% white, 7.9% Asian and 2.0% black. The concomitant diseases of patients in this trial included hypertension (38.6%), diabetes mellitus (9.0%), coronary artery disease (7.2%), active cancer (4.2%), and gastric or duodenal ulcer (3.8%). Concomitant medications included agents acting on renin-angiotensin system (27.9%), vasodilators (26.7%), serum lipid reducing agents (20.6%), NSAIDs (18.3%), beta-blockers (16.3%), calcium channel blockers (11.1%), aspirin (7.7%), and platelet inhibitors excluding ASA (0.9%). Patients randomized to warfarin had a mean percentage of time in the INR target range of 2.0 to 3.0 of 62% in the study.</p>    <p> <a name="p348378281396899680"></a>In study RE-MEDY, the protocol specified non-inferiority margin (2.85) for the hazard ratio was derived based on the point estimate of the historical warfarin effect. PRADAXA was demonstrated to be non-inferior to warfarin (dosed to target INR of 2 to 3) (Table 10) based on the primary composite endpoint (fatal PE or symptomatic non-fatal PE and/or DVT) and retains at least 63.0%&nbsp;of the historical warfarin effect. If the non-inferiority margin was derived based on the 50% retention of the upper limit of the 95% confidence interval, PRADAXA was demonstrated to retain at least 33.4% of the historical warfarin effect based on the composite primary endpoint.</p>    <a name="t36891228"></a>    <div class="scrollingtable">    <table border="0" frame="void" rules="none" width="75%">      <caption>       <span>Table 10 Primary Efficacy Endpoint for RE-MEDY – Modified ITT<span class="Sup">a</span> Population</span>      </caption>      <colgroup>       <col width="2.5%" />       <col width="24*" />       <col align="center" width="24*" />       <col align="center" width="24*" />      </colgroup>      <colgroup>       <col align="center" width="24*" />      </colgroup>      <tfoot>       <tr class="First Last">        <td colspan="5"><span class="Sup">a</span>Modified ITT analyses population consists of all randomized patients who received at least one dose of study medication.<br /> <span class="Sup">b</span>Number of patients with one or more event.<br /> <span class="Sup">c</span>Number of events. For patients with multiple events each event is counted independently.</td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PRADAXA<br />150 mg twice daily<br />N=1430<br />N (%)</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Warfarin<br />N=1426<br />N (%)</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Hazard ratio vs.<br />warfarin (95% CI)</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2">Primary Composite Endpoint<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">26 (1.8)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">18 (1.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">1.44 (0.78, 2.64)</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Fatal PE<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.07)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.07)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic non-fatal PE<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">10 (0.7)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">5 (0.4)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic recurrent DVT<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">17 (1.2)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">13 (0.9)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>      </tbody>     </table>   </div>    <p> <a name="p3638212281396899864"></a>In a randomized, parallel group, double-blind, pivotal trial, RE-SONATE, patients received PRADAXA 150 mg twice daily or placebo following 6 to 18 months of treatment with anticoagulation therapy for an acute VTE. The median treatment duration was 182 days. A total of 1343 patients were treated with a mean age of 55.8 years. The patient population was 55.5% male, 89.0% white, 9.3% Asian, and 1.7% black. The concomitant diseases of patients in this trial included hypertension (38.8%), diabetes mellitus (8.0%), coronary artery disease (6.0%), history of cancer (6.0%), gastric or duodenal ulcer (4.5%), and heart failure (4.6%). Concomitant medications included agents acting on renin-angiotensin system (28.7%), vasodilators (19.4%), beta-blockers (18.5%), serum lipid reducing agents (17.9%), NSAIDs (12.1%), calcium channel blockers (8.9%), aspirin (8.3%), and platelet inhibitors excluding ASA (0.7%). Based on the outcome of the primary composite endpoint (fatal PE, unexplained death, or symptomatic non-fatal PE and/or DVT), PRADAXA was superior to placebo (Table 11).</p>    <a name="t20515328"></a>    <div class="scrollingtable">    <table border="0" frame="void" rules="none" width="75%">      <caption>       <span>Table 11 Primary Efficacy Endpoint for RE-SONATE – Modified ITT<span class="Sup">a</span> Population</span>      </caption>      <colgroup>       <col width="2%" />       <col width="24*" />       <col align="center" width="25*" />       <col align="center" width="24*" />      </colgroup>      <colgroup>       <col align="center" width="25*" />      </colgroup>      <tfoot>       <tr class="First Last">        <td colspan="5"><span class="Sup">a</span>Modified ITT analyses population consists of all randomized patients who received at least one dose of study medication.<br /> <span class="Sup">b</span>Number of patients with one or more events.<br /> <span class="Sup">c</span>Number of events. For patients with multiple events each event is counted independently.</td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" colspan="2">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PRADAXA<br />150 mg twice daily<br />N=681<br />N (%)</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Placebo<br />N=662<br />N (%)</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Hazard ratio vs.<br />placebo (95% CI)</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" colspan="2">Primary Composite Endpoint<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">3 (0.4)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">37 (5.6)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">0.08 (0.02, 0.25)<br />p-value &lt;0.0001</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Fatal PE and unexplained death<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">0</td>       <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic non-fatal PE<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">1 (0.1)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">14 (2.1)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Toprule">&nbsp;</td>       <td class="Botrule Rrule Toprule">Symptomatic recurrent DVT<span class="Sup">c</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center">2 (0.3)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">23 (3.5)</td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp;</td>       </tr>      </tbody>     </table>   </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16  HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="Section_16"></a>  <a name="section-14"></a>   <p></p>    <p class="First"> <a name="p11056122"></a>PRADAXA 75 mg capsules have a cream-colored opaque cap imprinted with the Boehringer Ingelheim company symbol and a cream-colored opaque body imprinted with &quot;R75&quot;. The color of the imprinting is black. The capsules are supplied in the packages listed:</p>   <ul class="Disc">    <li>NDC 0597-0149-54&nbsp;&nbsp;&nbsp; Unit of use bottle of 60 capsules</li>    <li>NDC 0597-0149-60&nbsp;&nbsp;&nbsp; Blister package containing 60 capsules (10 x 6 capsule blister cards) </li>   </ul>   <p> <a name="p11273122"></a>PRADAXA 150 mg capsules have a light blue opaque cap imprinted with the Boehringer Ingelheim company symbol and a cream-colored opaque body imprinted with &quot;R150&quot;. The color of the imprinting is black. The capsules are supplied in the packages listed:</p>   <ul class="Disc">    <li>NDC 0597-0135-54&nbsp;&nbsp;&nbsp; Unit of use bottle of 60 capsules</li>    <li>NDC 0597-0135-60&nbsp;&nbsp;&nbsp; Blister package containing 60 capsules (10 x 6 capsule blister cards) </li>   </ul>   <p> <a name="p11284122"></a><span class="Italics"><span class="Underline"><span class="Emphasis">Bottles</span></span></span> </p>   <p> <a name="p11293122"></a>Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;-30&deg;C (59&deg;-86&deg;F). Once opened, the product must be used within 4 months. Keep the bottle tightly closed. Store in the original package to protect from moisture.</p>   <p> <a name="p11296122"></a><span class="Italics"><span class="Underline">Blisters</span></span> </p>   <p> <a name="p11305122"></a>Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;-30&deg;C (59&deg;-86&deg;F). Store in the original package to protect from moisture.</p>   <p> <a name="p11308122"></a>Keep out of the reach of children.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17  PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="Section_17"></a>  <a name="section-15"></a>   <p></p>    <p class="First"> <a name="p11524122"></a>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_17.1"></a>   <a name="section-15.1"></a>    <p></p>    <h2>17.1 Instructions for Patients</h2>    <ul class="Disc">     <li>Tell patients to take PRADAXA exactly as prescribed.</li>     <li>Remind patients not to discontinue PRADAXA without talking to the health care provider who prescribed it.</li>     <li>Keep PRADAXA in the original bottle to protect from moisture. Do not put PRADAXA in pill boxes or pill organizers.</li>     <li>When more than one bottle is dispensed to the patient, instruct them to open only one bottle at a time.</li>     <li>Instruct patient to remove only one capsule from the opened bottle at the time of use. The bottle should be immediately and tightly closed.</li>     <li>Advise patients not to chew or break the capsules before swallowing them and not to open the capsules and take the pellets alone. </li>     <li>Advise patients that the capsule should be taken with a full glass of water.</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_17.2"></a>   <a name="section-15.2"></a>    <p></p>    <h2>17.2 Bleeding</h2>    <p class="First"> <a name="p11561122"></a>Inform patients that they may bleed more easily, may bleed longer, and should call their health care provider for any signs or symptoms of bleeding.</p>    <p> <a name="p11564122"></a>Instruct patients to seek emergency care right away if they have any of the following, which may be a sign or symptom of serious bleeding:</p>    <ul class="Disc">     <li>Unusual bruising (bruises that appear without known cause or that get bigger)</li>     <li>Pink or brown urine</li>     <li>Red or black, tarry stools</li>     <li>Coughing up blood</li>     <li>Vomiting blood, or vomit that looks like coffee grounds</li>    </ul>    <p> <a name="p11790122"></a>Instruct patients to call their health care provider or to get prompt medical attention if they experience any signs or symptoms of bleeding:</p>    <ul class="Disc">     <li>Pain, swelling or discomfort in a joint</li>     <li>Headaches, dizziness, or weakness</li>     <li>Reoccurring nose bleeds</li>     <li>Unusual bleeding from gums</li>     <li>Bleeding from a cut that takes a long time to stop</li>     <li>Menstrual bleeding or vaginal bleeding that is heavier than normal</li>    </ul>    <p> <a name="p115675281396901455"></a>If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs or platelet inhibitors, advise patients to watch for signs and symptoms of spinal or epidural hematoma, such as back pain, tingling, numbness (especially in the lower limbs), muscle weakness, and stool or urine incontinence. If any of these symptoms occur, advise the patient to contact his or her physician immediately <span class="Italics">[see <a href="#Section_00">Boxed Warning</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_17.3"></a>   <a name="section-15.3"></a>    <p></p>    <h2>17.3 Gastrointestinal Adverse Reactions</h2>    <p class="First"> <a name="p11818122"></a>Instruct patients to call their health care provider if they experience any signs or symptoms of dyspepsia or gastritis:</p>    <ul class="Disc">     <li>Dyspepsia (upset stomach), burning, or nausea</li>     <li>Abdominal pain or discomfort </li>     <li>Epigastric discomfort, GERD (gastric indigestion)</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_17.4"></a>   <a name="section-15.4"></a>    <p></p>    <h2>17.4 Invasive or Surgical Procedures</h2>    <p class="First"> <a name="p12043122"></a>Instruct patients to inform their health care provider that they are taking PRADAXA before any invasive procedure (including dental procedures) is scheduled.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_17.5"></a>   <a name="section-15.5"></a>    <p></p>    <h2>17.5 Concomitant Medications</h2>    <p class="First"> <a name="p12051122"></a>Ask patients to list all prescription medications, over-the-counter medications, or dietary supplements they are taking or plan to take so their health care provider knows about other treatments that may affect bleeding risk (e.g., aspirin or NSAIDs) or dabigatran exposure (e.g., dronedarone or systemic ketoconazole).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_17.6"></a>   <a name="section-15.6"></a>    <p></p>    <h2>17.6 Prosthetic Heart Valves</h2>    <p class="First"> <a name="p21261522"></a>Instruct patients to inform their health care provider if they will have or have had surgery to place a prosthetic heart valve.</p>    <p> <a name="p10285922"></a> </p>    <p> <a name="p12058122"></a>Distributed by:<br />Boehringer Ingelheim Pharmaceuticals, Inc.<br />Ridgefield, CT 06877 USA</p>    <p> <a name="p12065122"></a>Copyright 2015 Boehringer Ingelheim Pharmaceuticals, Inc.<br />ALL RIGHTS RESERVED</p>    <p> <a name="p12070122"></a>75461-14<br />IT5060ABA212015</p>    <p> <a name="p12075122"></a>75457-14<br />IT5400Y</p>    <p> <a name="p25356622"></a>301841-09<br />IT5624M</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="Section_18"></a>  <a name="section-16"></a>   <p></p>   <h1></h1>   <p class="First"> <a name="p12290122"></a><span class="Bold"><span class="Emphasis">MEDICATION GUIDE<br />PRADAXA (pra dax a)<br />(dabigatran etexilate mesylate) <br />capsules</span></span> </p>   <p> <a name="p12303122"></a>Read this Medication Guide before you start taking PRADAXA and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>   <p> <a name="p12306122"></a> <br /> <span class="Bold"><span class="Emphasis">What is the most important information I should know about PRADAXA?</span></span> </p>   <ul class="Disc">    <li> <span class="Bold">For people taking PRADAXA for atrial fibrillation:</span> <br />People with atrial fibrillation (a type of irregular heartbeat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. PRADAXA lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking PRADAXA, you may have increased risk of forming a clot in your blood.<br /> <span class="Bold">Do not stop taking PRADAXA without talking to the doctor who prescribes it for you. Stopping PRADAXA increases your risk of having a stroke.</span> <br />PRADAXA may need to be stopped, if possible, prior to surgery or a medical or dental procedure. Ask the doctor who prescribed PRADAXA for you when you should stop taking it. Your doctor will tell you when you may start taking PRADAXA again after your surgery or procedure. If you have to stop taking PRADAXA, your doctor may prescribe another medicine to help prevent a blood clot from forming.<br /> </li>    <li>PRADAXA can cause bleeding which can be serious, and sometimes lead to death. This is because PRADAXA is a blood thinner medicine that lowers the chance of blood clots forming in your body.<br /> </li>    <li> <span class="Bold"><span class="Emphasis">You may have a higher risk of bleeding if you take PRADAXA and:</span></span>     <ul class="Disc">      <li>are over 75 years old</li>      <li>have kidney problems</li>      <li>have stomach or intestine bleeding that is recent or keeps coming back, or you have a stomach ulcer</li>      <li>take other medicines that increase your risk of bleeding, including:      <ul class="Circle">        <li>aspirin or aspirin containing products</li>        <li>long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li>        <li>warfarin sodium (Coumadin<span class="Sup">&reg;</span>, Jantoven<span class="Sup">&reg;</span>)</li>        <li>a medicine that contains heparin</li>        <li>clopidogrel bisulfate (Plavix<span class="Sup">&reg;</span>) </li>        <li>prasugrel (Effient<span class="Sup">&reg;</span>)</li>       </ul> </li>      <li>have certain kidney problems and also take the medicines dronedarone (Multaq<span class="Sup">&reg;</span>) or ketoconazole tablets (Nizoral<span class="Sup">&reg;</span>). <br />Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. <br /> </li>     </ul> </li>    <li>PRADAXA can increase your risk of bleeding because it lessens the ability of your blood to clot. While you take PRADAXA:     <ul class="Disc">      <li>you may bruise more easily</li>      <li>it may take longer for any bleeding to stop</li>     </ul> <br /> <span class="Bold"><span class="Emphasis">Call your doctor or get medical help right away if you have any of these signs or symptoms of bleeding:</span></span>     <ul class="Disc">      <li>unexpected bleeding or bleeding that lasts a long time, such as:      <ul class="Circle">        <li>unusual bleeding from the gums</li>        <li>nose bleeds that happen often</li>        <li>menstrual bleeding or vaginal bleeding that is heavier than normal</li>       </ul> </li>      <li>bleeding that is severe or you cannot control</li>      <li>pink or brown urine</li>      <li>red or black stools (looks like tar)</li>      <li>bruises that happen without a known cause or get larger</li>      <li>cough up blood or blood clots</li>      <li>vomit blood or your vomit looks like &quot;coffee grounds&quot;</li>      <li>unexpected pain, swelling, or joint pain</li>      <li>headaches, feeling dizzy or weak</li>     </ul> <br /> <span class="Bold"><span class="Emphasis">Take PRADAXA exactly as prescribed. Do not stop taking PRADAXA without first talking to the doctor who prescribes it for you. Stopping PRADAXA may increase your risk of a stroke.</span></span> <br /> PRADAXA may need to be stopped, if possible, for one or more days before any surgery, or medical or dental procedure. If you need to stop taking PRADAXA for <span class="Bold"><span class="Emphasis">any reason</span></span>, talk to the doctor who prescribed PRADAXA for you to find out when you should stop taking it. Your doctor will tell you when to start taking PRADAXA again after your surgery or procedure. <br /> <br /> <span class="Bold">Spinal or epidural blood clots (hematoma). </span>People who take a blood thinner medicine (anticoagulant) like PRADAXA, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if:    <ul class="Disc">      <li>a thin tube called an epidural catheter is placed in your back to give you certain medicine.</li>      <li>you take NSAIDs or a medicine to prevent blood from clotting</li>      <li>you have a history of difficult or repeated epidural or spinal punctures</li>      <li>you have a history of problems with your spine or have had surgery on your spine.</li>     </ul> <br />If you take PRADAXA and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), loss of control of the bowels or bladder (incontinence).<br /> <br /> <span class="Bold"><span class="Emphasis">See &quot;What are the possible side effects of PRADAXA?&quot; for more information about side effects.</span></span> </li>   </ul>   <p> <a name="p13088122"></a><span class="Bold"><span class="Emphasis">What is PRADAXA?</span></span> </p>   <p> <a name="p13095122"></a>PRADAXA is a prescription blood thinner medicine that lowers the chance of blood clots forming in your body. PRADAXA is used to:</p>   <ul class="Disc">    <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming and increase your risk of a stroke.</li>    <li>treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) and reduce the risk of them occurring again.</li>   </ul>   <p> <a name="p10278422"></a>PRADAXA is not for use in people with artificial (prosthetic) heart valves.</p>   <p> <a name="p13098122"></a>It is not known if PRADAXA is safe and works in children.</p>   <p> <a name="p13101122"></a><span class="Bold"><span class="Emphasis">Who should not take PRADAXA?</span></span> </p>   <p> <a name="p13314122"></a><span class="Bold"><span class="Emphasis">Do not take PRADAXA if you:</span></span> </p>   <ul class="Disc">    <li>currently have certain types of abnormal bleeding. Talk to your doctor before taking PRADAXA if you currently have unusual bleeding.</li>    <li>have had a serious allergic reaction to PRADAXA. Ask your doctor if you are not sure.</li>    <li>have ever had or plan to have a valve in your heart replaced</li>   </ul>   <p> <a name="p13329122"></a><span class="Bold"><span class="Emphasis">What should I tell my doctor before taking PRADAXA? </span></span> </p>   <p> <a name="p13336122"></a><span class="Bold">Before you take PRADAXA, tell your doctor if you:</span> </p>   <ul class="Disc">    <li>have kidney problems</li>    <li>have ever had bleeding problems</li>    <li>have ever had stomach ulcers</li>    <li>have any other medical condition</li>    <li>are pregnant or plan to become pregnant. It is not known if PRADAXA will harm your unborn baby.</li>    <li>are breastfeeding or plan to breastfeed. It is not known if PRADAXA passes into your breast milk. <br /> <br />Tell all of your doctors and dentists that you are taking PRADAXA. They should talk to the doctor who prescribed PRADAXA for you, before you have <span class="Bold"><span class="Emphasis">any</span></span> surgery, or medical or dental procedure. <br /> <br /> <span class="Bold"><span class="Emphasis">Tell your doctor about all the medicines you take, including</span></span> prescription and non-prescription medicines, vitamins, and herbal supplements.<br /> <br />Some of your other medicines may affect the way PRADAXA works. Certain medicines may increase your risk of bleeding. See &quot;<span class="Bold"><span class="Emphasis">What is the most important information I should know about PRADAXA</span></span>?&quot; <br /> <br />Especially tell your doctor if you take:     <ul class="Disc">      <li>rifampin (Rifater<span class="Sup">&reg;</span>, Rifamate<span class="Sup">&reg;</span>, Rimactane<span class="Sup">&reg;</span>, Rifadin<span class="Sup">&reg;</span>)</li>     </ul> <br />Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</li>   </ul>   <p> <a name="p13598122"></a><span class="Bold"><span class="Emphasis">How should I take PRADAXA?</span></span> </p>   <ul class="Disc">    <li>Your doctor will decide how long you should take PRADAXA. <span class="Bold">Do not stop taking PRADAXA without first talking with your doctor. Stopping PRADAXA may increase your risk of having a stroke or forming blood clots.</span> </li>    <li> <span class="Bold">Take PRADAXA exactly as prescribed by your doctor.</span> </li>    <li>Take PRADAXA capsules twice a day (approximately every 12 hours).</li>    <li>If you miss a dose of PRADAXA, take it as soon as you remember. If your next dose is less than 6 hours away, skip the missed dose. Do not take two doses of PRADAXA at the same time.</li>    <li>Swallow PRADAXA capsules whole. Do not break, chew, or empty the pellets from the capsule.</li>    <li>You can take PRADAXA with or without food.</li>    <li>You should take PRADAXA with a full glass of water.</li>    <li>Do not run out of PRADAXA. Refill your prescription before you run out. If you plan to have surgery, or a medical or a dental procedure, tell your doctor and dentist that you are taking PRADAXA. You may have to stop taking PRADAXA for a short time. See “What is the most important information I should know about PRADAXA?”.</li>    <li>If you take too much PRADAXA, go to the nearest hospital emergency room or call your doctor.</li>    <li>Call your doctor or healthcare provider right away if you fall or injure yourself, especially if you hit your head. Your doctor or healthcare provider may need to check you.</li>    <li>PRADAXA comes in a bottle or in a blister package.</li>    <li>Only open 1 bottle of PRADAXA at a time. Finish your opened bottle of PRADAXA before opening a new bottle.</li>    <li>After opening a bottle of PRADAXA, use within 4 months. See &quot;How should I store PRADAXA?&quot;</li>    <li>When it is time for you to take a dose of PRADAXA, only remove your prescribed dose of PRADAXA from your open bottle or blister package.</li>    <li>Tightly close your bottle of PRADAXA right away after you take your dose.</li>   </ul>   <p> <a name="p14090122"></a><span class="Bold"><span class="Emphasis">What are the possible side effects of PRADAXA?</span></span> </p>   <p> <a name="p14097122"></a><span class="Bold">PRADAXA can cause serious side effects, including:</span> </p>   <ul class="Disc">    <li>See &quot;What is the most important information I should know about PRADAXA?&quot;</li>    <li>Allergic Reactions. In some people, PRADAXA can cause symptoms of an allergic reaction, including hives, rash, and itching. Tell your doctor or get medical help right away if you get any of the following symptoms of a serious allergic reaction with PRADAXA:     <ul class="Square">      <li>chest pain or chest tightness</li>      <li>swelling of your face or tongue</li>      <li>trouble breathing or wheezing</li>      <li>feeling dizzy or faint</li>     </ul> </li>   </ul>   <p> <a name="p14122122"></a>Common side effects of PRADAXA include:</p>   <ul class="Disc">    <li>indigestion, upset stomach, or burning </li>    <li>stomach pain</li>   </ul>   <p> <a name="p14339122"></a>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>   <p> <a name="p14342122"></a>These are not all of the possible side effects of PRADAXA. For more information, ask your doctor or pharmacist.</p>   <p> <a name="p14345122"></a>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p> <a name="p14348122"></a><span class="Bold"><span class="Emphasis">How should I store PRADAXA?</span></span> </p>   <ul class="Disc">    <li>Store PRADAXA at room temperature between 59&deg;F to 86&deg;F (15&deg;C to 30&deg;C). After opening the bottle, use PRADAXA within 4 months. Safely throw away any unused PRADAXA after 4 months.</li>    <li> <span class="Bold"><span class="Emphasis">Keep PRADAXA in the original bottle or blister package to keep it dry (protect the capsules from moisture). Do not put PRADAXA in pill boxes or pill organizers.</span></span> </li>    <li> <span class="Bold"><span class="Emphasis">Tightly close your bottle of PRADAXA right away after you take your dose.</span></span> </li>   </ul>   <p> <a name="p14374122"></a><span class="Bold"><span class="Emphasis">Keep PRADAXA and all medicines out of the reach of children.</span></span> </p>   <p> <a name="p14381122"></a><span class="Bold"><span class="Emphasis">General information about PRADAXA</span></span> </p>   <p> <a name="p14594122"></a>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PRADAXA for a condition for which it was not prescribed. Do not give your PRADAXA to other people, even if they have the same symptoms that you have. It may harm them.</p>   <p> <a name="p14597122"></a>This Medication Guide summarizes the most important information about PRADAXA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about PRADAXA that is written for health professionals.</p>   <p> <a name="p14600122"></a>For more information, go to www.PRADAXA.com or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906, or scan here to go to www.PRADAXA.com.</p>   <p> <a name="p228332281396972355"></a><img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=pradaxa%2Dbar%2Dcode%2Ejpg" alt="pradaxa-bar-code" /></p>   <p> <a name="p14603122"></a><span class="Bold"><span class="Emphasis">What are the ingredients in PRADAXA?</span></span> </p>   <p> <a name="p14610122"></a>Active ingredient: dabigatran etexilate mesylate</p>   <p> <a name="p14613122"></a>Inactive ingredients: acacia, dimethicone, hypromellose, hydroxypropyl cellulose, talc, and tartaric acid. The capsule shell is composed of carrageenan, FD&amp;C Blue No. 2 (150 mg strength only), FD&amp;C Yellow No. 6, hypromellose, potassium chloride, titanium dioxide, and black edible ink.</p>   <p> <a name="p14616122"></a>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>   <p> <a name="p14619122"></a>Distributed by:<br />Boehringer Ingelheim Pharmaceuticals, Inc.<br />Ridgefield, CT 06877 USA</p>   <p> <a name="p14626122"></a>Revised: January 2015</p>   <p> <a name="p14629122"></a>The brands listed above are trademarks of their respective owners and are not trademarks of Boehringer Ingelheim Pharmaceuticals, Inc. The owners of these brands are not affiliated with and do not endorse Boehringer Ingelheim Pharmaceuticals, Inc., or its products.</p>   <p> <a name="p14632122"></a>Copyright 2015 Boehringer Ingelheim Pharmaceuticals, Inc.<br />ALL RIGHTS RESERVED</p>   <p> <a name="p14637122"></a>75461-14<br />IT5060ABA212015</p>   <p> <a name="p14848122"></a>75457-14<br />IT5400Y</p>   <p> <a name="p25361322"></a>301841-09<br />IT5624M</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="p1"></a>  <a name="section-17"></a>   <p></p>   <p class="First"> <a name="p8122789595"></a>PRADAXA (dabigatran etexilate mesylate) <br />75 mg capsules<br />NDC 0597-0149-54</p>   <div class="Figure">    <img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=carton014954%2Ejpg" alt="PRADAXA (dabigatran etexilate mesylate) capsules" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="p2"></a>  <a name="section-18"></a>   <p></p>   <br />   <p class="First"> <a name="p5122"></a>PRADAXA (dabigatran etexilate mesylate) <br />75 mg capsules<br />NDC 0597-0149-60</p>   <div class="Figure">    <img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=carton014960%2Ejpg" alt="Pradaxa Carton 75" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="p6"></a>  <a name="section-19"></a>   <p></p>   <br />   <p class="First"> <a name="p51221365772861"></a>PRADAXA (dabigatran etexilate mesylate) <br />75 mg capsules<br />NDC 0597-0149-54</p>   <div class="Figure">    <img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=label014954%2Ejpg" alt="NDC 0597-0149-54 label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="p3"></a>  <a name="section-20"></a>   <p></p>   <br />   <p class="First"> <a name="p51221365773014"></a>PRADAXA (dabigatran etexilate mesylate) <br />150 mg capsules<br />NDC 0597-0135-54</p>   <div class="Figure">    <img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=carton013554%2Ejpg" alt="NDC 0597-0135-54 carton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="p4"></a>  <a name="section-21"></a>   <p></p>   <br />   <p class="First"> <a name="p51221365773172"></a>PRADAXA (dabigatran etexilate mesylate) <br />150 mg capsules<br />NDC 0597-0135-60</p>   <div class="Figure">    <img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=carton013560%2Ejpg" alt="Pradaxa 150 Carton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="p5"></a>  <a name="section-22"></a>   <p></p>   <br />   <p class="First"> <a name="p51221365773314"></a>PRADAXA (dabigatran etexilate mesylate) <br />150 mg capsules<br />NDC 0597-0135-12</p>   <div class="Figure">    <img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=carton013512%2Ejpg" alt="NDC 0597-0135-12 carton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="p7"></a>  <a name="section-23"></a>   <p></p>   <br />   <p class="First"> <a name="p51221365773454"></a>PRADAXA (dabigatran etexilate mesylate) <br />150 mg capsules<br />NDC 0597-0135-54</p>   <div class="Figure">    <img src="image.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&name=label013554%2Ejpg" alt="NDC 0597-0135-54 label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>PRADAXA&nbsp; </strong> <br /> <span class="contentTableReg">dabigatran etexilate mesylate capsule</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0597-0149</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>DABIGATRAN ETEXILATE MESYLATE</strong> (UNII: SC7NUW5IIT) (DABIGATRAN - UNII:I0VM4M70GC)</td>          <td class="formItem">DABIGATRAN ETEXILATE</td>          <td class="formItem">75&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">WHITE (Cream colored)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE</td>          <td class="formLabel">Size</td>          <td class="formItem">18mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">R75</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0597-0149-54</td>          <td class="formItem">1 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">60 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0597-0149-60</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem"></td>          <td class="formItem">6 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:0597-0149-12</td>          <td class="formItem">2 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem"></td>          <td class="formItem">6 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA022512</td>          <td class="formItem">08/08/2011</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>PRADAXA&nbsp; </strong> <br /> <span class="contentTableReg">dabigatran etexilate mesylate capsule</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0597-0135</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>DABIGATRAN ETEXILATE MESYLATE</strong> (UNII: SC7NUW5IIT) (DABIGATRAN - UNII:I0VM4M70GC)</td>          <td class="formItem">DABIGATRAN ETEXILATE</td>          <td class="formItem">150&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">BLUE (Light Blue) ,&nbsp;WHITE (Cream colored)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE</td>          <td class="formLabel">Size</td>          <td class="formItem">22mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">R150</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0597-0135-54</td>          <td class="formItem">1 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">60 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0597-0135-12</td>          <td class="formItem">2 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem"></td>          <td class="formItem">6 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:0597-0135-60</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem"></td>          <td class="formItem">6 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA022512</td>          <td class="formItem">10/26/2010</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Boehringer Ingelheim Pharmaceuticals Inc. (603175944) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Registrant -&nbsp;</span>Boehringer Ingelheim Pharmaceuticals Inc. (603175944)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Boehringer Ingelheim Roxane Inc</td>      <td class="formItem"></td>      <td class="formItem">058839929</td>      <td class="formItem">LABEL(0597-0149, 0597-0135) , PACK(0597-0149, 0597-0135)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Boehringer Ingelheim Pharma GmbH and Co. KG</td>      <td class="formItem"></td>      <td class="formItem">551147440</td>      <td class="formItem">LABEL(0597-0149, 0597-0135) , ANALYSIS(0597-0149, 0597-0135) , MANUFACTURE(0597-0149, 0597-0135) , PACK(0597-0149, 0597-0135) , API MANUFACTURE(0597-0135, 0597-0149)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Bidachem S.p.a.</td>      <td class="formItem"></td>      <td class="formItem">429232812</td>      <td class="formItem">ANALYSIS(0597-0149, 0597-0135) , API MANUFACTURE(0597-0135, 0597-0149)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Micro-Macinazione SA</td>      <td class="formItem"></td>      <td class="formItem">480918515</td>      <td class="formItem">API MANUFACTURE(0597-0135, 0597-0149)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Boehringer Ingelheim Pharma GmbH and Co. KG</td>      <td class="formItem"></td>      <td class="formItem">340700520</td>      <td class="formItem">LABEL(0597-0149, 0597-0135) , PACK(0597-0149, 0597-0135)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Gfm Gesellschaft Fuer Micronisierung Mbh</td>      <td class="formItem"></td>      <td class="formItem">328866827</td>      <td class="formItem">API MANUFACTURE(0597-0135, 0597-0149)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22DABIGATRAN%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=DABIGATRAN" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=DABIGATRAN" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=DABIGATRAN+ETEXILATE+MESYLATE&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">PRADAXA- dabigatran etexilate mesylate capsule <br></h3>            <h4>Number of versions: 22</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Jan 27, 2015</td>                        <td>							                                30                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=163925">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 18, 2014</td>                        <td>							                                29                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=157681">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 29, 2014</td>                        <td>							                                28                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=152228">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 15, 2014</td>                        <td>							                                27                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=151089">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 26, 2014</td>                        <td>							                                26                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=149281">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 16, 2014</td>                        <td>							                                25                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=137065">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 19, 2013</td>                        <td>							                                24                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=127400">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 13, 2013</td>                        <td>							                                23                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=119336">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>May 1, 2013</td>                        <td>							                                21                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=106642">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 7, 2013</td>                        <td>							                                20                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=96968">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 27, 2012</td>                        <td>							                                19                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=96457">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 13, 2012</td>                        <td>							                                18                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=93270">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jul 9, 2012</td>                        <td>							                                17                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=82970">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jun 5, 2012</td>                        <td>							                                15                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=80701">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>May 2, 2012</td>                        <td>							                                14                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=78485">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 23, 2012</td>                        <td>							                                11                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=71706">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 21, 2011</td>                        <td>							                                10                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=67675">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 4, 2011</td>                        <td>							                                9                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=66560">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Oct 26, 2011</td>                        <td>							                                7                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=65889">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 9, 2011</td>                        <td>							                                3                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=62974">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Mar 16, 2011</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=50624">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 8, 2010</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=42444">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">PRADAXA- dabigatran etexilate mesylate capsule <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037045">1037045</a></td>                              <td>dabigatran etexilate 150 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037045">1037045</a></td>                              <td>dabigatran etexilate 150 MG Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037045">1037045</a></td>                              <td>dabigatran etexilate 150 MG (dabigatran etexilate mesylate 172.95 MG) Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037049">1037049</a></td>                              <td>Pradaxa 150 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037049">1037049</a></td>                              <td>dabigatran etexilate 150 MG Oral Capsule [Pradaxa]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037049">1037049</a></td>                              <td>Pradaxa 150 MG (dabigatran etexilate mesylate 172.95 MG) Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037049">1037049</a></td>                              <td>Pradaxa 150 MG Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037179">1037179</a></td>                              <td>dabigatran etexilate 75 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037179">1037179</a></td>                              <td>dabigatran etexilate 75 MG Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037181">1037181</a></td>                              <td>Pradaxa 75 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>11</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037181">1037181</a></td>                              <td>dabigatran etexilate 75 MG Oral Capsule [Pradaxa]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>12</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037181">1037181</a></td>                              <td>Pradaxa 75 MG (dabigatran etexilate mesylate 86.48 MG) Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>13</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1037181">1037181</a></td>                              <td>Pradaxa 75 MG Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">PRADAXA- dabigatran etexilate mesylate capsule <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APRADAXA%2D%20Dabigatran%20Etexilate%20Mesylate%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dba74e3cd%2Db06f%2D4145%2Db284%2D5fd6b84ff3c9%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    